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Recombinant organisms
Field of the invention
The invention relates to transgenic organisms, in particular transgenic microalgae, with
enhanced production of omega-3 long chain polyunsaturated fatty acids, related
methods and uses.
Introduction
Long chain polyunsaturated fatty acids (LC-PUFAs) have a carbon backbone of at least
2 0 carbons in length and contain multiple double-bond desaturations. Long chain
polyunsaturated fatty acids can be grouped into either an omega-3 (TO-3) or omega-6
(TO- 6 ) category based on the position of the first double bond from the methyl, or TO,
fatty acid terminus.
It is now well established that omega-3 LC-PUFAs, especially eicosapentaenoic acid
(EPA; 20:5 ∆ 5 ,8 ,1 1,14 ,17) and docosahexaenoic acid (DHA; 22:6 ∆ 4,7, 10 ,13 ,16 ,19) are
essential constituents of human nutrition and have key roles in growth and
development of infants and children and in maintaining health through their effects on
immune system (Voigt et al., 2000; Calder, 2003). There is growing evidence from
clinical studies that the presence of omega-3 LC-PUFAs in the human diet has
therapeutic effect in conditions such as cardiovascular diseases, obesity, metabolic
syndrome and eczema (Navarro et al., 2000; Nugent, 2004; Das, 2002).
Although marine fish is the main dietary source of EPA and DHA, the depletion of fish
stocks and pollution of the marine environment indicate an urgent need for an
alternative and sustainable source of LC-PUFAs. Marine microorganisms are the
primary producers of LC-PUFAs in the aquatic food chain and EPA- and DHA-rich
microalgae have been demonstrated to be a promising alternative source to fish oils for
human consumption. Thus, commercial cultivation of Crypthecodinium cohnii and
Schizochytrium sp. have been successfully developed for DHA production and some
marine microorganisms have demonstrated potential for the industrial production of
EPA (Nannochloropsis species, Phaeodactylum species, Nitzshia spp.) (Harwood and
Guschina, 2009). However, commercial production of highly valuable products like
omega-3 LC-PUFAs is expensive to maintain and represents a substantial
technological challenge.
One of the approaches to increase the levels of LC-PUFAS is to use acyl-CoA
dependent desaturases (Venegas-Caleron et al., 2010). In recent years, considerable
focus has been placed on engineering higher plants for the production of very long
chain polyunsaturated fatty acids (VLC-PUFAs) in their seed oils. Recently, the
advantages of using an acyl-CoA-dependent ∆ -desaturase from Ostreococcus tauri
(OtD6) to synthesize LC-PUFAs in transgenic Arabidopsis and Camelina plants have
been demonstrated (Sayanova O., et al, 2012, Ruiz-Lopez N., et al., 2012). These
studies indicate that the first step in the LC-PUFA pathway, the ∆ -desaturation, is
rate-limiting.
As an alternative way of producing LC-PUFAs, there is increasing interest in the
metabolic engineering of microalgae and genetic modification of algal strains
represents a promising strategy to produce sustainable omega-3 oils. Effective
recombinant engineering of microalgae to produce increased levels of LC-PUFAs for
commercial production would address a global need and microalgae manipulated in
this way would be useful as food additives and animal feed, including aquaculture, to
meet global demand.
Phaeodactylum tricornutum is an unicellular diatom which accumulates up to 30% EPA
and only traces of DHA and is considered a good source for the industrial production of
EPA (Molina Grima et al., 1996). The first labelling experiments with [14C]acetate
suggested that P. tricornutum synthesized EPA de novo by elongation and aerobic
desaturation of fatty acids (Moreno et al., 1979). In pulse-chase experiments Arao and
Yamada have demonstrated that EPA can be synthesized by 4 different routes and that
the preferred route involved intermediates of both omega-6 and omega-3 pathways
(Arao and Yamada, 1994). The majority of the EPA was found in galactolipids as
opposed to neutral lipids such as triacylglycerol (Arao et al., 1987; Yongmanitchai and
Ward, 1993). Recently, the genes encoding the ∆ 5- and ∆ -desaturases involved in
EPA biosynthesis in P. tricornutum have been cloned and characterized (Domergue et
al., 2002). It was shown that both desaturases were microsomal enzymes contributing
equally to both pathways and they supported the preferred route acting simultaneously
in omega-6 and omega-3 pathways. This suggests that ∆ 6- and ∆ 5- desaturation and
∆ 6- elongation involved in biosynthesis of EPA in P. tricornutum take place in the
endoplasmic reticulum (ER) and newly synthesized EPA is imported after into the
plastids. The presence of only minor amounts of all the intermediates of EPA
biosynthetic pathway indicates that P. tricornutum have developed highly efficient
mechanism towards the accumulation of EPA as a single end-product (Arao and
Yamada, 1994). In several microalgae DHA can be synthesized by the elongation of
EPA to docosapentaenoic acid (DPA; 22:5∆7,10, 13, 16, 19) by a specific ∆ δ-elongase,
with DPA then converted to DHA by a A4-desaturase.
The present invention is aimed at mitigating the shortcomings in the production of LC-
PUFAs in various organisms, in particular in algae.
Summary of the invention
The invention generally relates to transgenic organisms, in particular transgenic
microalgae, with enhanced production of LC-PUFAs, in particular omega-3 LC-PUFAs
such as DHA and/or EPA. The transgenic organisms, in particular transgenic
microalgae, express one or more heterologous nucleic acid encoding for a polypeptide
involved in the LC-PUFAs biosynthesis pathway. The invention also relates to methods
for making transgenic organisms, in particular transgenic microalgae, uses of the
transgenic organisms, in particular transgenic microalgae, and methods for increasing
the production of LC-PUFAs, in particular omega-3 LC-PUFAs, more particular DHA
and/or EPA in an organism, in particular microalgae. The invention also relates to
isolated nucleic acids and their uses in methods for the enhanced production of LC-
PUFAs, in particular omega-3 LC-PUFAs, in transgenic organisms.
The inventors have shown that microalgae can be manipulated using recombinant
methods to produce an increased amount of LC-PUFAs, in particular EPA and DHA
using heterologous gene expression. The inventors have surprisingly demonstrated
that heterologous expression of ∆ δ-elongase from Ostreococcus tauri alone results in
increased accumulation of DHA in P. tricornutum with DHA levels in transgenic strains
reaching up to 13% of total fatty acids. The inventors have also shown that
overexpression of OtD6 in P. tricornutum has a positive effect on EPA levels. These
findings provide evidence for the efficacy of expressing heterologous genes and
enhancing the LC-PUFAs biosynthetic pathway through metabolic engineering in
transgenic microalgae. Furthermore, other organisms that make EPA/DHA, including
animals and plants, can be manipulated in the same way by overexpression of ∆ 5-
elongase from Ostreococcus tauri.
Accordingly, in one aspect, the invention relates to a transgenic microalgae with
increased production of one or more omega-3 LC-PUFA. In one embodiment, the
omega-3 LC-PUFA is selected from DHA and/or EPA. In another aspect, the invention
relates to the use of a transgenic microalgae in producing omega-3 LC-PUFAs. In
another aspect, the invention relates to a method for producing transgenic microalgae
with increased omega-3 LC-PUFAs content. In another aspect, the invention relates to
a method for increasing production of one of more omega-3 LC-PUFA in microalgae
comprising
a) introducing and expressing in a microalgae a heterologous nucleic acid,
b) cultivating said microalgae and
c) obtaining said one of more omega-3 LC-PUFA from the transgenic
microalgae.
In another aspect, the invention relates to a method for increasing production of DHA in
microalgae. In another aspect, the invention relates to a method for increasing
production of EPA in microalgae.
The invention also relates to an oil isolated from a microalgae described herein or a
composition comprising a transgenic microalgae described or product therefrom herein
and uses thereof.
In another aspect, the invention relates to a method for making a feedstuff comprising
a) cultivating a transgenic microalgae described herein and
b) obtaining said one of more omega-3 LC-PUFA from the transgenic microalgae.
In another aspect, the invention relates to an isolated nucleic acids comprising SEQ ID
No. 7 or 9 encoding a ∆ -desaturase (Ost809A6) comprising SEQ ID No. 8 or 10, a
functional variant thereof or a ∆ -desaturase that has at least 75%, at least 80%, at
least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least
99% homology to SEQ ID No. 8 or 10 and uses thereof. The invention also relates to
an isolated nucleic acid comprising SEQ ID No. 15 or 17 encoding a A4-desaturase
(Ost809A4) comprising SEQ ID No. 16 or 18, a functional variant thereof or a ∆ 4-
desaturase that has at least 75%, at least 80%, at least 85%, at least 90%, at least
95%, at least 96%, at least 97%, at least 98%, at least 99% homology to SEQ ID No.
16 or 18 and uses thereof. In another aspect, the invention relates to an isolated
nucleic acid comprising SEQ ID No. 19 encoding A6-elongase (FcEL06) comprising
SEQ ID No. 20, a functional variant thereof or a A6-elongase that has at least 75%, at
least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least
98%, at least 99% homology to SEQ ID No. 20 and an isolated nucleic acid comprising
SEQ ID No. 2 1 encoding ∆ δ -desaturase comprising SEQ ID No. 22, a functional
variant thereof or a ∆ δ -desaturase that has at least 75%, at least 80%, at least 85%, at
least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%
homology to SEQ ID No. 22 and uses thereof.
In another aspect, the invention relates to the use of an isolated nucleic described
herein in increasing the production of omega-3 LC-PUFAs, in particular DHA and/or
EPA, in microalgae or higher plants.
Further, the invention relates to a transgenic organism, preferably a microalgae, with
increased DHA levels expressing a heterologous ∆ δ -elongase.
Figures
The invention is further described in the following non-limiting figures.
Fig. 1. EPA content in WT and transgenic P. tricornutum expressing O.tauri ∆ 6
desaturase under different growth conditions at two different growth stages: a) 20°C 60
µηιοΙ photons m-2s- ; b) 20°C 25 µηιοΙ photons m-2s- ; c) 18°C 25 µηιοΙ photons m-2s-1
Fig. 2a. Total fatty acid composition of WT and transgenic P. tricornutum cells
expressing OtElo5 during the exponential (E) and stationary (S) phases. Cultures were
grown at 20°C under constant illumination 60 µηιοΙ photons m 2 s with agitation. Each
value represents the mean ± SD of 3 separate experiments.
b. EPA< DPA and DHA content in WT and transgenic P. tricornutum expressing
OtElo5. Cultures were grown at 20°C 60 µηιοΙ m-2s-1 under constant agitation at 70
rpm. Each measurement is the average of 3 biological replicates.
Fig. 3. The acyl-CoA profiles of WT (A) and transgenic P. tricornutum expressing the
Ostreococcus Elo5 (B). The accumulation of LC-PUFA acyl-CoAs in B is boxed with a
dotted line.The internal standard (istd) is 17:00 acyl-CoA.
Fig. 4. EPA and DHA content in the total FA extracts of WT and transgenic OtElo5 P.
tricornutum cells.
Fig. 5A. The distribution of TAG species from WT and transgenic P. tricornutum at
stationary phase of growth.
Fig. 5B. The distribution of TAG species from WT and transgenic P. tricornutum at
different stages of growth.
Fig. 6. The distribution of DHA in TAG species from WT and transgenic P.tricornutum
expressing OtElo5 at different stages of the growth cycle: A-DHA in specific TAGs; B-
% of TAG containing DHA.
Fig. 7. Omega-3 PUFA biosynthetic pathway (schematic representation).
Fig. 8. Expression of Ost809A6-desaturase in transgenic yeast in the presence of the
exogenous substrate 18:3n-3 (ALA). (BPX72 column). Note the conversion of ALA to
the higher unsaturated form (SDA - arrowed). No conversion occurs with yeast strains
containing the empty vector (pYES2 - C), and only when the expression of the Ost809
desaturase is induced by the addition of galactose (Gal + ; B)
Fig. 9. Functional characterization of Ost809A6 in yeast (BPX72 column). Yeast cells
supplemented with LA and ALA. Expression of Ostreococcus 809 ∆6 in yeast,
supplemented with both 18:2 (LA) and 18:3 (ALA). Note the specific conversion of ALA,
but not LA, to a higher unsaturated. No conversion occurs with yeast strains containing
the empty vector (pYES2 - C), and only when the expression of the Ost809 desaturase
is induced by the addition of galactose (Gal + ; B)
Fig. 10. FAMEs profile of transgenic yeast expressing Ost809A4 desaturase in the
presence of DPA (C22:5n-3). Expression of Ostreococcus 809 ∆4 in yeast cells
supplemented with exogenous 22:5 (DPA). Note the conversion of 22:5n-3 to the
higher unsaturated form (22:6n-3; DHA - arrowed). No conversion occurs with yeast
strains containing the empty vector (pYES2 - C), and only when the expression of the
Ost809 D4 desaturase is induced by the addition of galactose (Gal + ; B). NB. These
C22 PUFAs are best resolved on a HP1 GC column - in this case, the
(poly)unsaturated fatty acids eluted earlier than less saturated forms - this is the
inverse compared to BPX72 column used above
Fig. 11. FAMEs profile of transgenic yeast expressing FcElo6 (BPX72 column). Yeast
were supplemented with 18:3n-6 (GLA). Expression of Fragilariopsis cylindrus Elo6 in
yeast cells supplemented with exogenous 18:3 (GLA). Note the conversion of 18:3 ALA
to the elongated form 20:3n-3 (arrowed). No conversion occurs with yeast strains
containing the empty vector (pYES2 - C), and only when the expression of the
Fragilariopsis Elo6 is induced by the addition of galactose (Gal + ; B).
Fig. 12. Phylogenetic tree showing relationship between n-3 specific Ost809A6
desaturase and other ∆ -desaturases.
Fig. 13. Expression of FcElo6 resulted in increase of DHA levels up to 14-17%. GC-MS
analysis of total FA profiles from Pt cells expressing FcElo6.
Fig. 14. Schematic representation of vector system pPTOS2.
Figure 15. Co-expression of two heterologous omega-3 LC-PUFA biosynthetic
activities in P. tricornutum. Fatty acid composition of Pt_WT, pPhOS2.1 (expressing
OtElo5) and pPhOS2.2 (expressing OtD6Pt and OtElo5) cells during the S phase of
growth at 16°C and 20°C. Values are the average of three experiments (+/- standard
error).
Fig. 16. Fatty acid composition of pPhOS_Ppglut (expressing OtElo5 and Ppglucose
transporter) cells during the S phase of growth at 20°C, 100 µηιοΙ m-2s-1 under constant
agitation at 70 rpm. N=1 .
Fig. 17. Fatty acid composition of pPhOS_Hsglut (expressing OtElo5 and human
glucose transporter) cells during the S phase of growth at 20°C, 100 µηιοΙ m-2s-1 under
constant agitation at 70 rpm. N=1 .
Fig. 18. Growth of t and pPhOS_Ppglut Pt cells in the dark.
Detailed description
The present invention will now be further described. In the following passages, different
aspects of the invention are defined in more detail. Each aspect so defined may be
combined with any other aspect or aspects unless clearly indicated to the contrary. In
particular, any feature indicated as being preferred or advantageous may be combined
with any other feature or features indicated as being preferred or advantageous.
The practice of the present invention will employ, unless otherwise indicated,
conventional techniques of microbiology, tissue culture, molecular biology, chemistry,
biochemistry and recombinant DNA technology, which are within the skill of the art.
Such techniques are explained fully in the literature.
The invention relates to the genetic manipulation of the fatty acid biosynthetic pathway
in microalgae. In particular, the invention relates to methods for increasing the
production of LC-PUFAs, in particular omega-3 LC-PUFAs, for example one of more
omega-3 LC-PUFA in an organism, in particular in microalgae.
Polyunsaturated fatty acids can be classified into two major families, depending on the
position (n) of the first double bond nearest the methyl end of the fatty acid carbon
chain. Thus, the omega-6 fatty acids (TO-6) have the first unsaturated double bond six
carbon atoms from the omega (methyl) end of the molecule and additionally have a
total or two or more double bonds, with each subsequent unsaturation occurring 3
additional carbon atoms toward the carboxyl end of the molecule. In contrast, the
omega-3 fatty acids (w-3) have the first unsaturated double bond three carbon atoms
away from the omega end of the molecule and additionally have a total of three or
more double bonds with each subsequent unsaturation occurring 3 additional carbon
atoms towards the carboxyl end of the molecule.
Table I summarizes the common names of omega-3 fatty acids and the abbreviations
that will be used throughout the specification:
Table I
There are a number of enzymes that are involved in the omega-3 PUFA biosynthetic
pathway as shown in figure 7 . These include desaturases and elongases.
A variety of genes involved in oil production have been identified through genetic
means in different organisms and the DNA sequences of some of these genes are
publicly available. Non-limiting examples are shown below:
Accession No. Description
AY131238 Argania spinosa ∆ -desaturase
Y0551 18 Echium pitardii var. pitardii ∆ -desaturase
AY0551 17 Echium gentianoides ∆ -desaturase
AF296076 Mucor rouxii ∆ -desaturase
AF007561 Borago officinalis ∆ -desaturase
L 11421 Synechocystis sp ∆ -desaturase
NM_031344 Rattus norvegicus ∆ 6 fatty acid desaturase
AF465283, Moritierella alpine ∆ 6 fatty acid desaturase
AF465282 Moritierella isabellina ∆ 6 fatty acid desaturase
AF419296 Pythium irregulare ∆ 6 fatty acid desaturase
AB052086 Mucor circinelloides D6d mRNA for ∆6 fatty acid
desaturase
AJ250735 Ceratodon purpureus mRNA forA6 fatty acid desaturase
AF126799 Homo sapiens ∆ 6 fatty acid desaturase
AF126798 Mus musculus ∆ 6 fatty acid desaturase
AF199596, Homo sapiens ∆ 5 desaturase
AF320509 Rattus norvegicus liver ∆ 5 desaturase
AB072976 Mus musculus D5D mRNA for ∆ 5 desaturase
AF489588 Thraustochytrium sp. ATCC21685 ∆ 5 desaturase
AJ510244 Phytophthora megasperma mRNA for ∆ 5 fatty acid
desaturase
AF419297 Pythium irregulare ∆ 5 fatty acid desaturase
AF07879 Caenorhabditis elegans ∆ 5 fatty acid desaturase
AF067654 Mortierella alpina ∆ 5 fatty acid desaturase
AB022097 Dictyostelium discloideum mRNA for ∆ 5 fatty acid
desaturase
AF489589.1 Thraustochytrium sp. ATcc21685 ∆ 4 fatty acid
desaturase
AY332747 Pavlova lutheri ∆ 4 fatty acid desaturase (desl) mRNA
AAG36933 Emericella nidulans oleate ∆ 12 desaturase
AF1 10509, Mortierella alpina ∆ 12 fatty acid desaturase mRNA
AAL13300 Mortierella alpina ∆ 12 fatty acid desaturase mRNA
AF417244 Mortierella alpine ATCC 16266 ∆ 12 fatty acid desaturase
AF161219 Mucor rouxii ∆ 12 desaturase mRNA
X86736 S Piruline platensis ∆ 12 desaturase
AF240777 Caenorhabdtitis elegans ∆ 12 desaturase
AB007640 Chlamydomonas reinhardtii ∆ 12 desaturase
AB075526 Chorella vulgaris ∆ 12 desaturase
AP002063 Arabidopsis thaliana microsomal ∆ 12 desaturase
NP_441622, Synechocystis sp. PCC6803 ∆ 15 desaturase
AAL36934 Perilla frutescens ∆ 15 desaturase
All references to sequence IDs herein are specifically incorporated by reference.
Additionally, the patent literature provides many additional DNA sequences of genes
(and/or details concerning several of the genes above and their methods of isolation)
involved in polyunsaturated fatty acid production (see, for example: U.S. Pat. No.
5,968,809 (∆ δ -desaturases); U.S. Pat No. 5,972,664 and U.S. Pat. No. 6,075,183 (∆ 5
desaturases); WO 91/13972 and U.S. Pat. No. 5,057,419 (A9-desaturases); WO
93/1 1245 (A15-desaturases); WO 94/1 1516. U.S. Pat. No. 5,443,974 and WO
03/099216 (A12-desaturases); U.S. 2003/0196217 A 1 (A17-desaturase); WO
02/090493 (A4-desaturases); and WO 00/12720 and U.S. 2002/01 39974A1
(elongases)).
The term "desaturases" as used herein refers to a polypeptide component of a multi-
enzyme complex that can desaturate, i.e. introduce a double bond in one or more fatty
acids to produce a mono- or polyunsaturated fatty acid or precursor of interest. Some
desaturates have activity on two or more substrates. It may be desirable to empirically
determine the specificity of a fatty acid desaturase by transforming a suitable host with
the gene for the fatty acid desaturase and determining its effect on the fatty acid profile
of the host. Nucleic acids that encode for desaturases are isolated from various
organisms can be used according to the various aspects of the invention and
examples are described herein, including Ostreococcus sp.
Desaturases include omega-3-desaturase, ∆ -desaturase, ∆ δ-desaturase, ∆ 12-
desaturase, A19-desaturase, A17-desaturase and A4-desaturase.
The term "elongase" as used herein refers to a polypeptide that can elongate a fatty
acid carbon chain to produce an acid two carbons longer than the fatty acid substrate
that the elongase acts upon. Nucleic acids that encode for elongases isolated from
various organisms can be used according to the various aspects of the invention and
examples are described herein, including Ostreococcus sp.
Examples of reactions catalyzed by elongase systems are the conversion of GLA to
DGLA, SDA to ETA, ARA to DTA and EPA to DPA. In general, the substrate selectivity
of elongases is somewhat broad but segregated by both chain length and the degree
and type of unsaturation.
For example, a C14/16 elongase will utilize a C14 substrate (e.g., myristic acid), a
C16/18 elongase will utilize a C16 substrate (e.g., palmitate), a C18/20 elongase will
utilize a C18 substrate (e.g., GLA, SDA, LA, ALA) and a C20/22 elongase (also
referred to as a ∆ δ-elongase) will utilize a C20 substrate (e.g., ARA, EPA).
Since some elongases have broad specificity, a single enzyme may be capable of
catalyzing several elongase reactions (e.g., thereby acting as both a C16/18 elongase
and C18/20 elongase). It may be desirable to empirically determine the specificity of a
fatty acid elongase by transforming a suitable host with the gene for the fatty acid
elongase and determining its effect on the fatty acid profile of the host.
Elongases include ∆ 6-, ∆ 5- and A9-elongases. ∆ δ-elongase is not generally viewed as
rate limiting in the production of DHA and it is generally assumed that the first step in
the LC-PUFA pathway, the D6-saturation, is rate-limiting.
Embodiments of the invention relating to the production of omega-3 LC-PUFAs in
transgenic microalgae are described below. A skilled person would understand that
these embodiments are not limited to transgenic microalgae, but can be applied to
other organisms to produce omega-3 LC-PUFAs. The organism may be an animal, for
example a mammal. In one embodiment, humans are specifically excluded. In another
embodiment, the organism is a plant, for example a crop plant.
In a first aspect, the invention relates to a transgenic microalgae with increased
production of omega-3 LC-PUFAs, for example one or more omega-3 LC-PUFA or total
omega-3 LC-PUFA content. According to the various aspects of the invention, the
omega-3 LC-PUFAs may be selected from SDA, ETA, EPA, DPA or DHA. In one
embodiment, the omega-3 LC-PUFAs is DHA. In another embodiment, the omega-3
fatty acid is EPA.
According to the various aspects of the invention described herein, the increase in the
production of DHA or EPA is measured as an individual content of different omega-3
LC-PUFAs in total fatty acids (TFA). In other words, the increase is measured as a
percentage of the total fatty acid content. Preferably, the increase is at least 2%, 3%,
4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15% or more compared to a
control microalgae (mol %).
In one embodiment, the omega-3 LC-PUFAs is DHA. In the transgenic microalgae of
the invention, the DHA content is increased by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%,
8%, 9%, 10%, 11%, 12%, 13%, 14%, 15% or more compared to a control microalgae.
In one embodiment, the omega-3 LC-PUFAs is DHA. In the transgenic microalgae of
the invention, the DHA content is at least 2 , at least 3 , at least 4 , at least 5 , at least 6 ,
at least 7 , at least 8 , at least 9 or at least 10 fold higher than in a control microalgae.
Preferably, the total DHA content is at least 10% of the total fatty acid content (mol %).
In another embodiment, the omega-3 LC-PUFAs is EPA. In the transgenic microalgae
according to the various aspects of the invention, the EPA content is increased by at
least 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%. Preferably,
the total EPA content is at least 20% of the total fatty acid content (mol %).
According to the various aspects of the invention, the total fatty acid content, LC-
PUFAs content, omega-3 LC-PUFAs content or the content of individual fatty acids
such as DHA is increased compared to a control microalgae. A control microalgae as
used herein is a microalgae which has not been modified according to the methods of
the invention. Accordingly, the control microalgae has not been genetically modified to
express a nucleic acid as described herein to alter LC-PUFA content. In one
embodiment, the control microalgae is a wild type microalgae. In another embodiment,
the control microalgae is a microalgae that does not carry a transgene according to the
methods described herein, but expresses a different transgene. The control microalgae
is typically of the same algae species.
The term "total fatty acids content" herein refers to the sum of all cellular fatty acids that
can be derivitized to fatty acid methyl esters by the base transesterification method in a
given sample (known as the art, for example as described in Sayanova et al., (1997);
Sayanova et al., (2003) FEBS Lett. 2003 May 8;542(1-3):100-4).
According to the various aspects of the invention, the increase is measured in the
stationary phase.
According to the various aspects of the invention, the term microalgae encompasses all
microalgae which have the capacity to make LC-PUFAs. The algae may be a
heterotrophic or autothrophic algae.
A skilled person would know that the term "microalgae" includes unicellular,
photosynthetic microorganisms from several distinct biological groups, comprising, for
example, eukaryotic chlorophyta, rhodophyta, heterokont, haptophyta divisions of algae
and prokaryotic cyanobacteria.
EPA has been found in a wide variety of marine microalgae including in the classes
Bacillariophyceae (diatoms), Chlorophyceae, Chrysophyceae, Cryptophyceae,
Eustigamatophyceae and Prasinophyceae (see Table II). Accordingly, according to the
various aspects of the invention, the microalgae may be selected from these orders,
classes or species.
According to the various aspects of the invention, the microalgae may be selected from
a microalgae listed in Table II.
Table II: Proportions of PUFAs in marine microalgae
*Emiliania huxleyhs the now accepted name for Coccolithus huxleyi
Omega-3 LC-PUFAs (% of Total Fatty acids)
Mircoalgae sp. EPA DHA References
(Order/class/sp.)
Chlorophyta (green algae)
Chlorophyceae
Chlorella minutissima 45.0 - Seto et al., (1984)
Prasinophyceae
Ostreococcus tauri 2.0 12.0 Wagner M . et al., (2010)
Ostreococcus lucimarinus 2.1 3.8 Ahmann et al., (201 1)
Hetermastrix rotundra 28 7 Yongmanitchai and Ward, (1989)
Haptophyta
Pavlovophyceae
11.6 9.1 Tonon et al., (2002)
Pavlova lutheri
Prymnesiophyceae
Isochrysis galbana
22.6 8.4 Molina Grima et al., (1995)
Emilinaia huxleyi * 17 - Yongmanitchai and Ward, (1989)
Cryptophyceae
Cryptomonadaceae
Cryptomonas maculate 17 - Yongmanitchai and Ward, (1989)
Chromonas sp. 12 6.6 Renaud et al., (1999)
Cryptomonas sp. 16 10 Yongmanitchai and Ward, (1989)
Rhodomonas sp. 8.7 4.6 Renaud et al., (1999)
Heterokont
Bacillariophyceae (diatoms)
Asterionella japonica 20 - Yongmanitchai and Ward, (1989)
Amphora coffeaformis 1.39 0.39 Renaud et al., (1999)
Biddulphia sinensis 24.0 1.0 Yongmanitchai and Ward, (1989)
Chaetoceros sp. 16.7 0.8 Renaud et al., (1999)
Cylindrotheca fusiformis 18.8 - Tan and Johns, (1996)
Fragilaria pinnata 6.8 1.0 Renaud et al., (1999)
Nitzchia angularis 2 1 - Kyle et al., (1992)
Navicula incerta 25.2 - Tan and Johns, (1996)
Navicula pelliculosa 9.4 - Tan and Johns, (1996)
Navicula saprophila 16.0 - Kitano et al., (1997)
Nitzschia closterium 15.2 - Renaud et al., (1994)
Nitzschia frustulum 23.1 - Renaud et al., (1994)
Nitzschia laevis 19.1 - Wen and Chen, (2001)
Phaeodactylum tricornutum 34.5 - Yongmanitchai and Ward, (1991)
Skeletonema costatum 29.2 3.4 Blanchemain and Grizeau,
Thalassiosira pseudonana 12.2 - (1999)
Tonon et al., (2002)
Chrysophyceae (golden algae)
Monochrysis lutheri 19 - Yongmanitchai and Ward,
(1989); Kyle, (1992)
Pseudopedinella sp. 27 - Yongmanitchai and Ward, (1989)
Crisosphaera carterae 20 - Yongmanitchai and Ward, (1989)
C.elongate 28 Yongmanitchai and Ward, (1989)
Eustigmatophyceae
Nannochloropsis salina 15 - Yongmanitchai and Ward, (1989)
Nannochloropsis sp. 35 - Sukenik, (1991)
Nannochloris sp. 27 - Yongmanitchai and Ward, (1989)
Monodus subterraneus 32.9 - Quiang et al., (1997)
In one embodiment, autotrophic microalgae which are as the primary producers of
PUFAs are preferred. For example, the microalgae may be selected from
Phaeodactylum, Nannochloropsis, Thraustochytrium or Schizochytrium. Other genera
include Spirulina, Dunaliella, Chlorella, Thalassiosira, Isochrysis, Porphyridium,
Nannochloropsis, Pavlova, Chaetoceros, Crypthecodinium, Fraigilariopsi and Nitzshia.
For example, the microalgae may be selected from Chaetoceros calcitrans, Isochrysis
galbana, Pavlova lutheri, Pseudoisochrysis paradoxa, Tetraselmis suecica and
Skeletonema costatum, Nannochloropsis oculata, Thalassiosira pseudonana, Pavlova
lutheria, Porphyridium irregular, Crypthecodinium cohnii, Porphyridium purpureum and
Porphyridium omentum.
In one embodiment, the microalgae is a diatom. Diatoms are brown algae found
throughout marine and freshwater ecosystems that are responsible for around 20% of
global primary productivity. A defining feature of diatoms is their ornately patterned
silicified cell wall (known as frustule), which display species-specific nanoscale-
structures.
The diatom may be a centric diatoms or a pennate diatom. In one embodiment, the
diatom belongs to the order of Naviculales. In one embodiment, the diatom is P.
tricornutum or Thalassiosira pseudonana. In a preferred embodiment, the diatom is P.
tricornutum. In another embodiment, the diatom is Fragilariopsis sp. for example
Fragilariopsis cylindrus.
A skilled person would understand that the aspects of the invention are not limited to P.
tricornutum. Indeed, a skilled person would understand that the invention can be
applied to any microalgae that has the capacity to synthesise EPA and/or DHA.
The transgenic microalgae according to the various aspects of the invention expresses
one or more heterologous transgenes which encode for one or more nucleic acid
involved in the biosynthesis of LC-PUFAs. "Heterologous" with respect to sequence
means a sequence that originates from a foreign species, or, if from the same species,
is substantially modified from its native form in composition and/or genomic locus by
deliberate human intervention. The heterologous transgene is preferably derived or
isolated from a microalgae. In one embodiment, the heterologous transgene is derived
or isolated from Prasinophyceae, for example Ostreococcus sp. Sequences of
heterologous transgenes may be modified to be codon optimised for expression in the
target organism. Thus, the invention relates to transgenic organisms obtained through
recombinant methods.
For example, the heterologous transgene may encode for one or more of a ∆ 15-
desaturase, a ∆ -desaturase, a ∆ δ-desaturase, a A4-desaturase, a A12-desaturase, a
∆ δ-elongase, ∆ -elongase or combinations thereof.
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In one embodiment, the transgenic microalgae expresses a heterologous nucleic acid
encoding a ∆δ-elongase. Thus, in one aspect, the invention relates to a transgenic
microalgae expressing a nucleic acid encoding a ∆ δ-elongase. For example, the
transgenic microalgae expresses a nucleic acid encoding a ∆δ-elongase, but does not
0 express any other transgene encoding for a polypeptide involved in the regulation of
the LC-PUFAs biosynthetic pathway. In other embodiments, the transgenic microalgae
expresses a nucleic acid encoding a ∆ δ-elongase and one or more additional
heterologous transgene involved in the regulation of the LC-PUFAs biosynthetic
pathway, for example a ∆ -desaturase such as OtD6 as shown in example 4 . Thus,
δ embodiments where nucleic acids encoding a ∆δ-elongase and a ∆ -desaturase are
co-expressed are specifically part of the invention. ∆δ-elongases and ∆ -desaturases
are as defined herein.
In one embodiment, the transgenic microalgae described herein co-expresses a
0 heterologous nucleic acid which is not involved in the regulation of the LC-PUFAs
biosynthetic pathway, for example a glucose transporter gene as shown in example δ
together with a heterologous nucleic acid involved in the regulation of the LC-PUFAs
biosynthetic pathway such as Ο ί ΕΙοδ . As shown in the example, a vector can be used
allowing co-expression of two heterologous nucleic acids involved in the regulation of
δ different traits - one for omega-3s, and one which allows the alga to be grown in the
dark, by the expression of a glucose transporter. If the cells are then provided with an
exogenous carbon source such as glucose, they can grow in the dark. Thus, in one
embodiment, an exogenous carbon source such as glucose is provided when culturing
algae expressing a gene involved in the regulation of the LC-PUFAs biosynthetic
0 pathway such as Ο ί ΕΙοδ and a glucose reporter. Examples of nucleic acids that can be
used according to the invention encoding a glucose reporter are shown in SEQ ID No.
23 and SEQ ID No. 2δ . Respective peptides are shown in SEQ ID No. 24 and SEQ ID
No. 26.
As used herein, the words "nucleic acid", "nucleic acid sequence", "nucleotide", or
"polynucleotide" are intended to include DNA molecules (e.g. cDNA or genomic DNA),
RNA molecules (e.g., mRNA), natural occurring, mutated, synthetic DNA or RNA
molecules, and analogs of the DNA or RNA generated using nucleotide analogs. It can
be single-stranded or double-stranded. Such nucleic acids or polynucleotides include,
but are not limited to, coding sequences of structural genes, anti-sense sequences,
and non-coding regulatory sequences that do not encode mRNAs or protein products.
These terms also encompass a gene. The term "gene" or "gene sequence" is used
broadly to refer to a DNA nucleic acid associated with a biological function. Thus,
genes may include introns and exons as in genomic sequence, or may comprise only a
coding sequence as in cDNAs, and/or may include cDNAs in combination with
regulatory sequences. In one embodiment of the various aspects of the invention,
cDNA sequences synthetic (deduced) open reading frames, analogous to cDNA are
preferred.
For the purposes of the invention, "transgenic", "transgene" or "recombinant" means
with regard to, for example, a nucleic acid sequence, an expression cassette, gene
construct, a vector or an autonomous replicating element such as an artificial
chromosome comprising the nucleic acid sequence or an organism transformed with
the nucleic acid sequences, expression cassettes or vectors according to the invention,
all those constructions brought about by recombinant methods in which either
(a) the nucleic acid sequences encoding proteins useful in the methods of the
invention, or
(b) genetic control sequence(s) which is operably linked with the nucleic acid
sequence according to the invention, for example a promoter, or
(c) a) and b)
are not located in their natural genetic environment or have been modified by
recombinant methods, such as mutagenesis, it being possible for the modification to
take the form of, for example, a substitution, addition, deletion, inversion or insertion of
one or more nucleotide residues. The natural genetic environment is understood as
meaning the natural genomic or chromosomal locus in the original microalgae or the
presence in a genomic library.
A transgenic microalgae for the purposes of the invention is thus understood as
meaning a microalgae which comprises within its nuclear and or plastidial genome a
heterologous polynucleotide. The heterologous polynucleotide is preferably stably
integrated within the genome such that the polynucleotide is passed on to successive
generations. The heterologous polynucleotide may be integrated into the genome
alone or as part of a recombinant DNA construct.
In the context of the present invention, a ∆δ-elongase catalyzes the conversion of EPA
to DPA. Thus, any nucleic acid that encodes a ∆δ-elongase that catalyzes the
conversion of EPA to DPA may be used according to the various aspects of the
invention as a transgene. In one embodiment, the ∆δ-elongase used in the present
invention is derived or isolated from Ostreococcus, preferably Ostreococcus tauri.
Preferably, the ∆ -elongase is Ο ί ΕΙοδ derived or isolated from Ostreococcus tauri. In
one embodiment, the transgenic microalgae according to the invention expresses a
nucleic acid comprising SEQ ID No. 1, a functional variant thereof or a sequence that
encodes for a ∆δ-elongase wherein said elongase has at least 60%, at least δδ% , at
least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%,
at least 97%, at least 98% or at least 99% homology to SEQ ID No. 2 . In a preferred
embodiment, the microalgae is P. triconutum and the nucleic acid encodes a ∆5-
elongase comprising or consisting of SEQ ID No. 2 .
A functional variant as used according to the aspects of the invention is a biologically
active variant. For example, a biologically active variant of SEQ ID No. 1 is a nucleic
acid sequence, which, when expressed in a microalgae such as P. tricornutum,
increases production of DHA. The term variant includes sequences which have been
altered for codon optimisation for expression in the target organism for example for
expression in P. tricornutum.
Thus, it is understood, as those skilled in the art will appreciate, that the aspects of the
invention, which use certain polynucleotides including the methods and uses,
encompasses more than the sequence specified, but also include alterations in the
peptide that do not affect the biological function. For example, alterations in a nucleic
acid fragment which result in the production of a chemically equivalent amino acid at a
given site, but do not affect the functional properties of the encoded polypeptide, are
well known in the art. For example, a codon for the amino acid alanine, a hydrophobic
amino acid, may be substituted by a codon encoding another less hydrophobic residue,
such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine.
Similarly, changes which result in substitution of one negatively charged residue for
another, such as aspartic acid for glutamic acid, or one positively charged residue for
another, such as lysine for arginine, can also be expected to produce a functionally
equivalent product. Nucleotide changes which result in alteration of the N-terminal and
C-terminal portions of the polypeptide molecule would also not be expected to alter the
activity of the polypeptide. Each of the proposed modifications is well within the routine
skill in the art, as is determination of retention of biological activity of the encoded
products.
In one embodiment, the said nucleic acid according to the various aspects of the
invention is operably linked to a regulatory sequence.
The terms "regulatory element" is used interchangeably herein with "control sequence"
and "promoter" and all terms are to be taken in a broad context to refer to regulatory
nucleic acid sequences capable of effecting expression of the sequences to which they
are ligated. The term "promoter" typically refers to a nucleic acid control sequence
located upstream from the transcriptional start of a gene and which is involved in
recognising and binding of RNA polymerase and other proteins, thereby directing
transcription of an operably linked nucleic acid. Encompassed by the aforementioned
terms are transcriptional regulatory sequences derived from a classical eukaryotic
genomic gene (including the TATA box which is required for accurate transcription
initiation, with or without a CCAAT box sequence) and additional regulatory elements
(i.e. upstream activating sequences, enhancers and silencers) which alter gene
expression in response to developmental and/or external stimuli, or in a tissue- specific
manner. Also included within the term is a transcriptional regulatory sequence of a
classical prokaryotic gene, in which case it may include a -35 box sequence and/or -10
box transcriptional regulatory sequences. The term "regulatory element" also
encompasses a synthetic fusion molecule or derivative that confers, activates or
enhances expression of a nucleic acid molecule in a cell, tissue or organ.
Suitable promoters are identified in the examples. For example, if the microalgae is P.
tricornutum, the promoter may be the P. tricornutum promoter fcpA. However, a skilled
person would understand that other promoters can also be used. For example, suitable
promoters may also be selected from inducible promoters which respond to specific
environmental or chemical stimuli.
The term "operably linked" as used herein refers to a functional linkage between the
promoter sequence and the gene of interest, such that the promoter sequence is able
to initiate transcription of the gene of interest.
The transgene may be part of a vector which, in addition to one or more regulatory
sequences also comprises selection markers. These are known in the art.
Transformation of microalgae may be carried out by standard procedures known in the
art, for example by particle bombardment or electroporation.
The transgenic microalgae expressing a nucleic acid encoding a ∆ δ -elongase is
characterised by an increase in DHA and DPA compared to a control microalgae. In
particular, the increase, as measured as a percentage of the total fatty acid content is
at least 2 , at least 3 , at least 4 , at least 5 , at least 6 , at least, at least 8 , at least 9 or at
least 10 fold higher than in a control microalgae. Specifically, the DHA content is at
least 2 , at least 3 , at least 4 , at least 5 , at least 6 , at least, at least 8 , at least 9 or at
least 10 fold higher than in a control microalgae. Preferably, the total DHA content is at
least 10% of the total LC-PUFAs content (%mol). In one embodiment, the transgenic
microalgae expressing a nucleic acid encoding a ∆ δ -elongase does not express a
second transgene encoding for another polypeptide involved in the regulation of the
LC-PUFAs pathway, preferably in the regulation of the omega-3 LC-PUFAs pathway.
In one embodiment of the various aspects of the invention, the transgenic microalgae
expressing a heterologous nucleic acid encoding a ∆ δ -elongase may further express
one or more additional heterologous nucleic acid encoding for one or more polypeptide
involved in the regulation of the LC-PUFAs pathway, preferably in the regulation of the
omega-3 LC-PUFAs pathway. In other words, the transgenic microalgae comprises
one or more further transgene encoding for one or more polypeptide involved in the
regulation of the LC-PUFAs pathway. The polypeptide is preferably selected from any
desaturase or elongase involved in the omega-3 PUFA biosynthetic pathway as shown
in figure 7 . Any combination of desaturase and elongase may also be used. Thus, the
nucleic acid may encode for one or more of a ∆ ΐ -desaturase, a ∆ -desaturase, a ∆ 5-
desaturase, a A4-desaturase, a ∆ -desaturase, a ∆ δ-elongase, ∆ -elongase or
combinations thereof.
In one embodiment, the nucleic acid encodes a ∆ -desaturase. In the context of the
present invention, a ∆ -desaturase catalyzes the conversion of ALA to SDA and also
LA to GLA. A6-Desaturases are described in WO 93/06712, US 5,614, 393, US
5614393, WO 96/21022, WO 02/1557 and WO 99/271 11 and their application to
production in transgenic organisms is also described, e.g. in WO 98/46763, WO
98/46764 and WO 98/46765. In one embodiment, the ∆ δ -desaturase used in the
present invention is derived or isolated from Ostreococcus, preferably OtD6 from
Ostreococcus tauri (Domergue et al (2005), AY746357). In one embodiment, the
nucleic acid comprises SEQ ID No. 3 or 5 and encodes a 6A-desaturase comprising or
consisting of SEQ ID No. 4 or 6 , a functional variant thereof or a polypeptide that
encodes for a 6A-desaturase that has at least 50%, at least 55%, at least 60%, at least
65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%,
at least 98% or at least 99% homology to SEQ ID No. 4 or 6 .
In another embodiment, the A6-desaturase is from the microalgae Ostreococcus RCC
809. Preferably, the nucleic acid comprises SEQ ID No. 7 or 9 and encodes a 6∆ -
desaturase from the microalgae Ostreococcus RCC 809 comprising or consisting of
SEQ ID No. 8 or 10, a functional variant thereof or a sequence that encodes for a 6∆ -
desaturase that has at least 50%, at least 55%, at least 60%, at least 65%, at least
70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%,
at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at
least 99% homology to SEQ ID No. 8 or 10.
In another embodiment, the nucleic acid encodes for a A4-desaturase. According to the
various aspects of the invention, a A4-desaturase may be derived or isolated from E.
huxleyi. Thus, in one embodiment, the nucleic acid comprises SEQ ID No. 11 encoding
a A4-desaturase comprising or consisting of SEQ ID No. 12, a functional variant
thereof or a A4-desaturase that has at least 50%, at least 55%, at least 60%, at least
65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%,
at least 98% or at least 99% homology to SEQ ID No. 12.
In another embodiment, the A4-desaturase is derived or isolated from T. pseudonana.
Thus, in one embodiment, the nucleic acid comprises SEQ ID No. 13 encoding a ∆ 4-
desaturase comprising or consisting of SEQ ID No. 14, a functional variant thereof or a
A4-desaturase that has at least 50%, at least 55%, at least 60%, at least 65%, at least
70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%,
at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at
least 99% homology to SEQ ID No. 14.
In another embodiment, the A4-desaturase is derived or isolated from Ostreococcus
RCC809. In one embodiment, the nucleic acid comprises SEQ ID No. 15 or 17
encoding a A4-desaturase comprising or consisting of SEQ ID No. 16 or 18, a
functional variant thereof or a A4-desaturase that has at least 50%, at least 55%, at
least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least
90%, at least 9 1% , at least 92%, at least 93%, at least 94%, at least 95%, at least 96%,
at least 97%, at least 98% or at least 99% homology to SEQ ID No. 16 or 18.
In another embodiment, a A6-elongase is from Fragilariopsis cylindrus. In one
embodiment, the nucleic acid comprises SEQ ID No 19 encoding a A6-elongase
comprising or consisting of SEQ ID No. 20, a functional variant thereof or a ∆ 6-
elongase that has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%,
at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at
least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at
least 99% homology to SEQ ID No. 20.
In another embodiment, a ∆ δ-desaturase is from Fragilariopsis cylindrus. In one
embodiment, the nucleic acid comprises SEQ ID No 2 1 encoding a ∆ δ-desaturase
comprising or consisting of SEQ ID No. 22, a functional variant thereof or a ∆ 6-
elongase that has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%,
at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at
least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at
least 99% homology to SEQ ID No. 22.
In another aspect, the transgenic microalgae of the invention expresses a heterologous
nucleic acid encoding a ∆ -desaturase, a ∆ δ-desaturase, a A4-desaturase, ∆ 6-
elongase or combinations thereof. These enzymes are defined herein.
In one aspect, a transgenic microalgae of the invention expresses a heterologous
nucleic acid encoding a ∆ -desaturase. Thus, in another aspect, the invention also
relates to transgenic microalgae expressing a heterologous nucleic acid encoding a
∆ -desaturase. For example, the transgenic microalgae expresses a nucleic acid
encoding a ∆ -desaturase, but does not express any other transgene involved in the
regulation of the LC-PUFAs biosynthetic pathway. In other embodiments, the
transgenic microalgae expresses a ∆ -desaturase and additional transgenes involved
in the regulation of the LC-PUFAs biosynthetic pathway, for example a ∆ δ-elongase
such as OtElo5 as shown in the examples.
In one embodiment, the microalgae is P. triconutum. In one embodiment, the nucleic
acid comprising or consisting of SEQ ID No. 3 or 5 encodes a ∆ -desaturase or a
sequence that encodes for a ∆ -desaturase that has at least 50%, at least 55%, at
least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%,
at least 97%, at least 98%, at least 99% homology to SEQ ID No. 4 or 6 . In a preferred
embodiment, the microalgae is P. triconutum and the nucleic acid encodes a ∆ 6-
desaturase comprising or consisting of SEQ ID No. 4 or 6 .
The transgenic microalgae expressing a nucleic acid encoding a A6-desaturase is
characterised in that the total fatty acids content, specifically the omega 3 LC-PUFA
content, is altered compared to a control microalgae. In particular, the omega-3 LC-
PUFA content is increased by at least 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%,
12%, 13%, 14%, 15% or more. Specifically, the EPA content is increased by at least
2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15% compared to a
control microalgae. Preferably, the total EPA content is at least 20% of the total LC-
PUFAs content (mol %). Moreover, the DHA content in the transgenic algae is also
increased by at least 0.5%.
In one embodiment, the various aspects of the invention exclude embodiments that
relate to the production of biofuels.
In another aspect, the invention relates to a method for producing transgenic
microalgae with increased omega-3 LC-PUFA content comprising introducing and
expressing in a microalgae a heterologous nucleic acid which encodes for a
polypeptide involved in the LC-PUFAs biosynthetic pathway. The omega-3 fatty acid
may be selected from ALA, SDA, ETA, EPA, DPA or DHA. In one embodiment, the
omega-3 LC-PUFAs is DHA. In another embodiment, the omega-3 fatty acid is EPA.
The nucleic acid may encode ∆ -desaturase, ∆ δ-desaturase, A4-desaturase, ∆ 5-
elongase, ∆ -elongase or combinations thereof.
In one embodiment, the method relates to producing transgenic microalgae with
increased DHA levels said method comprising transforming a microalgae with a
heterologous nucleic acid encoding a ∆ δ-elongase. According to this embodiment, the
method may further comprise transforming said microalgae with one or more additional
heterologous nucleic acid that regulates the production of omega-3 fatty acids, for
example transforming with a nucleic acid encoding a ∆ -desaturase. In another
embodiment, no additional nucleic acid that regulates the production of omega-3 fatty
acids is introduced into said microalgae and expressed as heterologous nucleic acids.
In another embodiment, the invention relates to a method for producing transgenic
microalgae with increased EPA levels said method comprising transforming a
microalgae with a nucleic acid encoding a ∆ -desaturase. According to this
embodiment, the method may further comprise transforming said microalgae with one
or more additional nucleic acid that regulates the production of omega-3 LC-PUFAs. In
another embodiment, no additional nucleic acid that regulates the production of omega-
3 fatty acids is introduced into said microalgae.
In one embodiment, the method comprises transforming said microalgae with one or
more additional nucleic acid that does not regulates the production of omega-3 LC-
PUFAs, for example a glucose transporter gene.
Microalgae obtained or obtainable by those methods are also within the scope of the
invention.
In another aspect, the invention relates to a method for increasing production of one of
more omega-3 LC-PUFA in microalgae comprising
a) cultivating a transgenic microalgae described herein and
b) obtaining said one of more omega-3 LC-PUFA from the transgenic
microalgae.
Specifically, the invention relates to a method for increasing the production of one or
more omega-3 LC-PUFAs in microalgae comprising:
a) introducing and expressing in a microalgae a heterologous nucleic acid which
encodes for a polypeptide involved in the LC-PUFAs biosynthetic pathway,
b) cultivating a transgenic microalgae expressing said heterologous nucleic acid and
c) obtaining one or more omega -3 fatty acid from the transgenic microalgae.
The transgenic microalgae is as described herein and is cultivated under conditions
which allow for the production of one or more omega-3 LC-PUFAs. The nucleic acid
may encode a A15-desaturase, a A6-desaturase, a ∆ δ-desaturase, a A4-desaturase, a
A12-desaturase, ∆ δ-elongase, A6-elongase or combinations thereof as described
herein.
In one embodiment, the method relates to increasing DHA production in microalgae
comprising
a) introducing and expressing in a microalgae a heterologous nucleic acid encoding a
∆ δ-elongase,
b) cultivating a transgenic microalgae expressing said heterologous nucleic acid and
c) obtaining DHA from the transgenic microalgae.
The microalgae as described herein. The ∆ δ-elongase is as described herein. In one
embodiment, the microalgae does not include and express a second heterologous
nucleic acid encoding an enzyme involved in the regulation of the synthesis of omega-3
LC-PUFAs. In another embodiment, the microalgae includes and expresses a second
heterologous nucleic acid encoding a polypeptide involved in the regulation of the
synthesis of omega-3 LC-PUFAs. In another embodiment, the microalgae includes and
expresses a second heterologous nucleic acid encoding a polypeptide not involved in
the regulation of the synthesis of omega-3 LC-PUFAs, for example a glucose
transporter. The transgenic microalgae is cultivated under conditions which allow for
the production of DHA.
In one embodiment, the method relates to increasing DHA production in microalgae
comprising
a) introducing and expressing in P. triconutum a heterologous nucleic acid
encoding a ∆ δ -elongase,
b) cultivating P. triconutum expressing said heterologous nucleic acid and
c) obtaining said DHA from P. triconutum.
The microalgae as described herein. The ∆ δ -elongase is as described herein. In one
embodiment, the microalgae does not include and express a second heterologous
nucleic acid encoding an enzyme involved in the regulation of the synthesis of omega-3
LC-PUFAs. In another embodiment, the microalgae includes and expresses a second
heterologous nucleic acid encoding an enzyme involved in the regulation of the
synthesis of omega-3 LC-PUFAs. In another embodiment, the microalgae includes and
expresses a second heterologous nucleic acid encoding a polypeptide not involved in
the regulation of the synthesis of omega-3 LC-PUFAs, for example a glucose
transporter.
P. triconutum is cultivated under conditions which allow for the production of DHA.
These conditions will be apparent to the skilled person. For example, preferred culture
conditions for P. triconutum are about 20°C under constant illumination in about 60-80
µηιοΙ photons m- 2s 1 . In one embodiment, the method comprises transforming said
microalgae with one or more additional nucleic acid that does not regulates the
production of omega-3 LC-PUFAs, for example a glucose transporter gene and
supplying an exogenous carbon source. The algae can be grown in the dark.
In another embodiment, the method relates to increasing EPA in microalgae
comprising:
a) introducing and expressing in a microalgae a heterologous nucleic acid
encoding a ∆ -desaturase,
b) cultivating the transgenic microalgae and
c) obtaining said EPA from the transgenic microalgae.
The microalgae as described herein The ∆ -desaturase is as described herein. The
microalgaeis cultivated under conditions which allow for the production of EPA.
In one embodiment, the method relates to increasing EPA production in microalgae
comprising
a) introducing and expressing in P. triconutum a heterologous nucleic acid
encoding a ∆ -desaturase,
b) cultivating P. triconutum and
c) obtaining said EPA from P. triconutum.
The microalgae as described herein The ∆ -desaturase is as described herein. P.
triconutum is cultivated under conditions which allow for the production of EPA.
These conditions will be apparent to the skilled person. For example, preferred culture
conditions for P. triconutum are about 20°C under constant illumination in about 0-
δθµηιο ΐ photons m- 2s 1 or preferably about 18°C under constant illumination in about
25µηιοΙ photons m- 2s 1 . In one embodiment, the method comprises transforming said
microalgae with one or more additional nucleic acid that does not regulates the
production of omega-3 LC-PUFAs, for example a glucose transporter gene and
supplying an exogenous carbon source. The algae can be grown in the dark.
In another aspect, the invention relates to a method for the manufacture of an oil, lipid
or fatty acid composition comprising
a) cultivating a transgenic microalgae as described herein under conditions which allow
for the production one or more omega-3 LC-PUFAs and
b) obtaining said one or more omega-3 LC-PUFAs from the transgenic microalgae.
In preferred embodiment, the omega-3 LC-PUFAs is DHA or EPA.
In another aspect, the invention relates to an omega-3 LC-PUFAs or oil isolated from a
transgenic microalgae as described herein.
The fatty acids produced by the processes of the present invention can be isolated
from the microalgae in the form of an oil, a lipid or a free fatty acid. One embodiment of
the invention is therefore oils, lipids or fatty acids or fractions thereof which have been
produced by the methods of the invention, especially preferably oil, lipid or a fatty acid
composition comprising EPA or DHA and being derived from the transgenic
microalgae.
The term "oil", or "lipid" is understood as meaning a fatty acid mixture comprising
unsaturated, preferably esterified, fatty acid(s). The oil or lipid is preferably high in
omega-3 polyunsaturated or, advantageously, esterfied fatty acid(s). In a particularly
preferred embodiment the oil or lipid has a high ALA, ETA, EPA, DPA and/or DHA
content, preferably a high EPA and/or DHA content.
For the analysis, the fatty acid content can, for example, be determined by gas
chromatography after converting the fatty acids into the methyl esters by
transesterification of the lipids such as triacylglycerides and/or phospholipids.
The omega-3 polyunsaturated acids produced in the method of the present invention,
for example EPA and DHA, may be in the form of fatty acid derivatives, for example
sphingolipids, phosphoglycerides, lipids, glycolipids, phospholipids, monoacylglycerol,
diacylgycerol, triacylgylcerol or other fatty acid esters.
The omega-3 and other polyunsaturated fatty acids which are present can be liberated
for example via treatment with alkali, for example aqueous KOH or NaOH, or acid
hydrolysis, advantageously in the presence of an alcohol such as methanol or ethanol,
or via enzymatic cleavage, and isolated via, for example, phase separation and
subsequent acidification via, for example H2S0 4. The fatty acids can also be liberated
directly without the above-described processing step.
If further purification is necessary, standard methods can be employed. Such methods
may include extraction, treatment with urea, fractional cyrstallization, HPLC, fractional
distillation, silica gel chromatography, high-speed centrifugation or distillation, or
combinations of these techniques. Protection of reactive groups, such as the acid or
alkenyl groups, may be done at any step through known techniques (e.g. alkylation,
iodination, use of butylated hydroxytoluene (BHT). Methods used include methylation
of the fatty acids to produce methy esters. Similarly, protecting groups may be removed
at any step. Desirably, purification of fractions containing, for example, ALA, STA, ETA,
EPA, DPA and DHA may be accomplished by treatment with urea and/or fractional
distillation.
Large scale purification methods of fatty acids from algae are known in the art. For
example, a microalgae strain is cultivated to increase cell density using
photobioreactors, open ponds, race ways or hybrid systems. Algal cells are separated
from culture media by filtration, flocculation or centrifugation, followed by drying to
improve extraction. Lipid extraction is then commonly performed using a non-water
miscible organic solvent. Larger scale extraction is typically carried out with hexane as
a solvent. Subsequently, unsaturated fatty acids are separated from the total lipids by
fractional (molecular) distillation or winterization, whereby oil temperature is reduced to
precipitate the more saturated lipids. Further processing to improve the quality, shelf-
life and quantity of PUFA oil can include filtration, bleaching, deodorization, polishing
and antioxidant addition. These methods are all known to a person skilled in the art.
In another aspect, the invention also relates to the use of the transgenic organism,
preferably microalgae, as described herein in the production of fatty acids, preferably a
omega-3 fatty acids. The invention encompasses the use of a transgenic organism,
preferably microalgae, as described herein or of the oil, lipid, the fatty acids obtained
from a transgenic organism, preferably microalgae, as described herein in feedstuffs,
foodstuffs, cosmetics, nutriceutical or pharmaceuticals. The invention encompasses the
use of a transgenic organism, preferably microalgae as described herein, in producing
feedstuffs, foodstuffs, cosmetics, nutriceutical or pharmaceuticals. In another aspect,
the invention also relates to the use of the transgenic microalgae, as described herein
as a feedstuff for animals, preferably fish.
In another aspect, the invention also relates to a composition comprising the transgenic
microalgae as described herein or a fatty acid, preferably a omega-3 fatty acid, oil, or
lipid obtained from said microalgae. In a preferred embodiment, the composition
comprises the transgenic microalgae as described herein or a product obtained or
obtainable therefrom., such as an oil. In one embodiment, the composition may be a
pharmaceutical composition, a cosmetic, a foodstuff, including food supplements, or
feedstuff for animals. In particular, the invention relates to a foodstuff comprising the
transgenic microalgae as described herein or fatty acid, preferably a omega-3 fatty
acid, oil, or lipid obtained from said algae. This can be in the form of a dietary
supplement, including fish oils. The invention also relates to an animal feed, especially
for aquaculture, comprising the transgenic microalgae as described herein or fatty acid,
preferably a omega-3 fatty acid, oil, or lipid obtained from said algae.
In another aspect, the invention relates to a composition comprising the transgenic
microalgae as described herein, a fatty acid, preferably a omega-3 fatty acid, oil, or
lipid obtained from said microalgae for use in medicine. In particular, the composition
may be used to lower both blood pressure and heart rate in hypertensive individuals
reducing the risk of sudden death, reduce inflammation, and to reduce the long-term
risk of atherosclerosis and ischemic heart disease. The composition may also be used
to treat eczema or metabolic syndrome. Also, a DHA rich diet is associated with
increased cognitive abilities and depression and has a positive effect on arthritis and
type I I diabetes (Horrocks et al, 1999). Thus, the invention also relates to a composition
comprising the transgenic microalgae as described herein or fatty acid, preferably a
omega-3 fatty acid, oil, or lipid obtained from said microalgae for use in the treatment
or prevention of cardiovascular conditions, including atherosclerosis, thrombosis, high
blood pressure, myocardial infarction and atherosclerosis, inflammatory conditions,
depression, cognitive decline, arthritis, and type I I diabetes. Also encompassed in the
scope of the invention are methods of treating or preventing cardiovascular and
inflammatory conditions, depression, cognitive decline, arthritis and type I I diabetes
administering a composition comprising a therapeutic amount of the transgenic
microalgae as described herein, a fatty acid, preferably a omega-3 fatty acid, oil, or
lipid obtained from said microalgae to a patient in need thereof. The invention also
relates to the use of a composition comprising the transgenic microalgae as described
herein in the manufacture of a medicament for treating cardiovascular conditions,
including atherosclerosis, thrombosis, high blood pressure, myocardial infarction and
atherosclerosis, inflammatory conditions, depression, cognitive decline, arthritis, and
type I I diabetes.
In preferred embodiments, the composition may comprise or be obtained from a
transgenic microalgae expressing a nucleic acid encoding a ∆ -desaturase and/or a
transgenic microalgae expressing a nucleic acid encoding a ∆ δ -elongase as described
herein.
The inventors have shown that microalgae can be manipulated using recombinant
methods to produce an increased amount of LC-PUFAs, in particular EPA and DHA
using heterologous gene expression. The inventors have surprisingly demonstrated
that heterologous expression of ∆ δ -elongase from Ostreococcus tauri alone results in
increased accumulation of DHA in P. tricornutum with DHA levels in transgenic strains
reaching up to 13% of total fatty acids. A skilled person would understand that the
invention is not restricted to algae and can indeed be applied to any organism that
makes EPA/DHA. Thus, the invention also relates to a transgenic organism with
increased DHA levels expressing a heterologous ∆ δ -elongase, preferably a ∆ 5-
elongase from Ostreococcus tauri. In one embodiment, no other transgenes are
expressed in the transgenic organism. In another embodiment, further transgenes may
be expressed as described herein. Furthermore, the invention also relates to methods
for increasing the production of DHA in a transgenic organism. This is achieved by
expressing a heterologous ∆ δ -elongase, preferably a ∆ δ -elongase from Ostreococcus
tauris in said organism. Details of said methods are described herein.
The organism may be an animal, for example a mammal. In one embodiment, humans
are specifically excluded. In another embodiment, the organism is a plant, for example
a monocot or dicot plant, for example crop plant. Crop plants include but are not limited
to maize, rice, wheat, oilseed rape/canola, sorghum, soybean, sunflower, alfalfa,
potato, tomato, tobacco, grape, barley, pea, bean, field bean, lettuce, cotton, sugar
cane, sugar beet, broccoli or other vegetable brassicas or poplar.
In another aspect, the invention relates to isolated nucleic acids encoding for novel
forms of the desaturases and elongases which may be useful in the heterologous
reconstitution of the omega-3 long chain polyunsaturated fatty acid biosynthetic
pathway in algae and higher plants. Specifically, the invention relates to isolated
nucleic acids encoding ∆ -desaturase (Ost809A6), A4-desaturase (Ost809A4) and ∆ 6-
elongase (FcEL06) and their corresponding polypeptides.
In one embodiment, the invention relates to an isolated nucleic acids comprising SEQ
ID No. 7 or 9 encoding ∆ -desaturase (Ost809A6) comprising or consisting of SEQ ID
No. 8 or 10, a functional variant thereof or a ∆ -desaturase that has at least 50%, at
least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least
85%, at least 90%, at least 9 1% , at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% homology to SEQ ID No. 8 or 10.
The sequence may also be codon optimised for expression the target organism.
In one embodiment, the invention relates to an isolated nucleic acid comprising SEQ ID
No. 15 or 17 encoding a A4-desaturase (Ost809A4) comprising or consisting of SEQ ID
No. 16 or 18, a functional variant thereof or a A4-desaturase that has at least 50%, at
least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99% homology to SEQ ID No. 16 or
18. The sequence may also be codon optimised for expression the target organism.
In one embodiment, the invention relates to an isolated nucleic acid comprising SEQ ID
No. 19 encoding A6-elongase (FcEL06) comprising or consisting of SEQ ID No. 20, a
functional variant thereof or a A6-elongase that has at least 50%, at least 55%, at least
60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%,
at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at
least 97%, at least 98%, at least 99% homology to SEQ ID No. 20. The sequence may
also be codon optimised for expression the target organism.
In one embodiment, the invention relates to an isolated nucleic acid comprising SEQ ID
No. 2 1 encoding a ∆ δ-desaturase comprising or consisting of SEQ ID No. 22, a
functional variant thereof or a ∆ δ-desaturase that has at least 50%, at least 55%, at
least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%,
at least 97%, at least 98%, at least 99% homology to SEQ ID No. 22. The sequence
may also be codon optimised for expression the target organism.
The invention also relates to a vector comprising one or more of the isolated nucleic
acids as specified above. The vector may further comprise a regulatory sequence.
The invention also relates to a transgenic microalgae with increased production of
omega-3 LC-PUFAs wherein said microalgae expresses a nucleic acid comprises SEQ
ID No. 7 , 9 , 15, 17, 19 or 2 1 or a sequence that encodes for a peptide that has at least
75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%,
at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%
homology to SEQ ID No. 8 , 10, 16, 18, 20 or 22. Compositions comprising the
transgenic microalgae, oil or lipids isolated therefrom and uses of as described herein
in medicine or the formulation of a medicament, methods of treatment or feedstuff,
foodstuff, pharmaceuticals or nutriceutical are also within the scope of the invention.
Without wishing to be bound by theory, the inventors believe that the activities of these
nucleotides will prove useful in the heterologous reconstitution of the omega-3 long
chain polyunsaturated fatty acid biosynthetic pathway in algae and plants. For
example, the superior substrate-preference of the Ost809A6 enzyme distinguishes it
from other Ostreococcus D6-desaturases, and can be used to maximise the flux of
substrate through the n-3 pathway. Similarly, the Ost809A4 activity will prove useful in
the specific conversion of DPA to DHA in transgenic photosynthetic organisms, whilst
the FcEL06 activity provides a means by which GLA can be elongated to 20:3n-6.
In another embodiment, the invention therefore relates to the use of an isolated nucleic
acid selected from a nucleic acid comprising or consisting of SEQ ID No. 7 or 9
encoding ∆ -desaturase (Ost809A6) comprising or consisting of SEQ ID No. 8 or 10, a
functional variant thereof or a ∆ -desaturase that has at least 50%, at least 55%, at
least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least
90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% homology to
SEQ ID No. 8 or 10, a nucleic acid comprising or consisting of SEQ ID No. 16 or 18, a
functional variant thereof or a A4-desaturase that has at least 50%, at least 55%, at
least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%,
at least 97%, at least 98%, at least 99% homology to SEQ ID No. 16 or 18, a nucleic
acid comprising or consisting of SEQ ID No. 19 encoding A6-elongase (FcEL06)
comprising or consisting of SEQ ID No. 20, a functional variant thereof or a ∆ 6-
elongase that has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%,
at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at
least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least
99% homology to SEQ ID No. 20 or a nucleic acid comprising or consisting of SEQ ID
No. 2 1 encoding a ∆ δ-desaturase comprising or consisting of SEQ ID No. 22, a
functional variant thereof or a ∆ δ-desaturase that has at least 50%, at least 55%, at
least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least
96%, at least 97%, at least 98%, at least 99% homology to SEQ ID No. 22 in the
production of a transgenic organism with increased omega-3 fatty acid content. In
particular, the invention relates to the use of isolated nucleic acids encoding a ∆6-
desaturase (Ost809A6) to maximise the flux of substrate through the n-3 pathway and
produce enhanced levels of EPA and/or DHA. In another embodiment, the invention
relates to the use of an isolated nucleic acid encoding a A4-desaturase (Ost809A4) to
convert DPA to DHA. In another embodiment, the invention relates to the use of an
isolated nucleic acid encoding a ∆ -elongase to elongate GLA to 20:3.
In another embodiment, the invention relates to the use of an isolated nucleic acid
selected from a nucleic acid comprising or consisting of SEQ ID No. 19 encoding ∆6-
elongase (FcEL06) comprising or consisting of SEQ ID No. 20, a functional variant
thereof or a ∆ -elongase that has at least 50%, at least 55%, at least 60%, at least
65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least
9 1% , at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%,
at least 98%, at least 99% homology to SEQ ID No. 20 or a nucleic acid comprising or
consisting of SEQ ID No. 2 1 encoding ∆ δ-desaturase comprising or consisting of SEQ
ID No. 22, a functional variant thereof or a ∆ δ-desaturase that has at least 50%, at
least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least
95%, at least 96%, at least 97%, at least 98%, at least 99% homology to SEQ ID No.
22 in increasing DHA content. As shown in the examples and figure 13, DHA is
increased by at least 10%, for example 14-17%.
In another embodiment, the invention relates to a method for producing a transgenic
organism with increased of omega-3 LC-PUFAs production, in particular DHA and/or
EPA, comprising transforming an organism with an isolated nucleic acid comprising or
consisting of SEQ ID No. 7 or 9 encoding A6-desaturase (Ost809A6) comprising or
consisting of SEQ ID No. 8 or 10, a functional variant thereof or a A6-desaturase that
has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%,
at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%
homology to SEQ ID No. 8 or 10, a nucleic acid comprising or consisting of SEQ ID
No. 16 or 18, a functional variant thereof or a A4-desaturase that has at least 50%, at
least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least
95%, at least 96%, at least 97%, at least 98%, at least 99% homology to SEQ ID No.
16 or 18, a nucleic acid comprising or consisting of SEQ ID No. 19 encoding ∆6-
elongase (FcEL06) comprising or consisting of SEQ ID No. 20, a functional variant
thereof or a A6-elongase that has at least 50%, at least 55%, at least 60%, at least
65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%,
at least 98%, at least 99% homology to SEQ ID No. 20 or a nucleic acid comprising or
consisting of SEQ ID No. 2 1 encoding a ∆ δ-desaturase comprising or consisting of
SEQ ID No. 22, a functional variant thereof or a ∆ δ-desaturase that has at least 50%,
at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at
least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at
least 95%, at least 96%, at least 97%, at least 98%, at least 99% homology to SEQ ID
No. 22.
In one embodiment, the invention relates to a method for producing a transgenic
organism with increased of DHA production, comprising transforming an organism with
an isolated nucleic acid nucleic acid selected from a nucleic acid comprising or
consisting of SEQ ID No. 19 encoding A6-elongase (FcEL06) comprising or consisting
of SEQ ID No. 20, a functional variant thereof or a A6-elongase that has at least 50%,
at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at
least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at
least 95%, at least 96%, at least 97%, at least 98%, at least 99% homology to SEQ ID
No. 20 or a nucleic acid comprising or consisting of SEQ ID No. 2 1 encoding a ∆ 5-
desaturase comprising or consisting of SEQ ID No. 22, a functional variant thereof or a
∆ δ-desaturase that has at least 50%, at least 55%, at least 60%, at least 65%, at least
70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least
92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% homology to SEQ ID No. 22 in increasing DHA content. As shown in the
examples and Figures 13, DHA is increased by at least 10%, for example 14-17%.
In another embodiment, the invention relates to a method for increasing the production
of omega-3 fatty acid transforming an organism with an isolated nucleic acid
comprising or consisting of SEQ ID No. 7 or 9 encoding A6-desaturase (Ost809A6)
comprising or consisting of SEQ ID No. 8 or 10, a functional variant thereof or a ∆6-
desaturase that has at least 50%, at least 55%, at least 60%, at least 65%, at least
70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%,
at least 97%, at least 98%, at least 99% homology to SEQ ID No. 8 or 10, a nucleic
acid comprising or consisting of SEQ ID No. 16 or 18, a functional variant thereof or a
A4-desaturase that has at least 50%, at least 55%, at least 60%, at least 65%, at least
70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least
92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% homology to SEQ ID No. 16 or 18, a nucleic acid comprising or consisting
of SEQ ID No. 19 encoding A6-elongase (FcEL06) comprising or consisting of SEQ ID
No. 20, a functional variant thereof or a A6-elongase that has at least 50%, at least
55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%,
at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, at least 99% homology to SEQ ID No. 20 or a
nucleic acid comprising or consisting of SEQ ID No. 2 1 encoding a ∆ δ-desaturase
comprising or consisting of SEQ ID No. 22, a functional variant thereof or a ∆ 5-
desaturase that has at least 50%, at least 55%, at least 60%, at least 65%, at least
70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least
92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99% homology to SEQ ID No. 22.
In one embodiment, the invention relates to a method for increasing the production of
omega-3 fatty acid transforming an organism with an isolated nucleic acid nucleic acid
selected from a nucleic acid comprising or consisting of SEQ ID No. 19 encoding ∆6-
elongase (FcEL06) comprising or consisting of SEQ ID No. 20, a functional variant
thereof or a A6-elongase that has at least 50%, at least 55%, at least 60%, at least
65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%,
at least 98%, at least 99% homology to SEQ ID No. 20 or a nucleic acid comprising or
consisting of SEQ ID No. 2 1 encoding a ∆ δ-desaturase comprising or consisting of
SEQ ID No. 22, a functional variant thereof or a ∆ δ-desaturase that has at least 50%,
at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at
least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%,at least
95%, at least 96%, at least 97%, at least 98%, at least 99% homology to SEQ ID No.
22 in increasing DHA content. As shown in the examples and Figures 13, DHA is
increased by at least 10%, for example 14-17%.
In one embodiment of the methods, method may further comprise transforming said
microalgae with one or more additional nucleic acid that regulates the production of
omega-3 fatty acids. In another embodiment, no additional nucleic acid that regulates
the production of omega-3 fatty acids are introduced into said microalgae. Other
heterologous nucleic acids, for example encoding a glucose transporter may be
included.
In another aspect, invention relates to a host cell transformed with a vector comprising
one or more of the isolated nucleic acids defined herein, specifically an isolated nucleic
acid comprising SEQ ID No. 1, 3 , 5 , 7 , 9 , 15, 17, 19 or 2 1. In one embodiment, the host
cell is transformed with a vector comprising one of the isolated nucleic acids defined
herein and no other heterologous transgenes involved in the regulation of the LC-
PUFAs biosynthetic pathway are expressed in said organism.
The host cell may be an algae or a higher plant cell. For example, the host cell is a
microalgae. In one embodiment, the host cell is a diatom. The host cell may also
comprise one or more additional transgene. For example, the host cell may be a
transgenic microalgae described herein expressing a nucleic acid encoding for a ∆ 5-
elongase.
The transgenic organism according to the methods described above may a microalgae
or a higher plant. Preferably, the transgenic organism according to the methods
described is a microalgae. The term microalgae is defined elsewhere herein and
includes a diatom. In one embodiment, the microalgae is P. tricornutum. The term
higher plant includes monocot and dicot plants. In one embodiment, the plant is a crop
plant as described herein.
All references cited in this disclosure are herewith incorporated by reference with
respect to their entire disclosure content and the disclosure content specifically
mentioned in this application.
"and/or" where used herein is to be taken as specific disclosure of each of the multiple
specified features or components with or without the other at each combination unless
otherwise dictated. For example "A, B and/or C" is to be taken as specific disclosure of
each of (i) A , (ii) B, (iii) C, (iv) A and B, (v) B and C or (vi) A and B and C, just as if each
is set out individually herein.
Unless context dictates otherwise, the descriptions and definitions of the features set
out above are not limited to any particular aspect or embodiment of the invention and
apply equally to all aspects and embodiments which are described.
The invention is further described in the following non-limiting examples.
Examples
Example 1 Generation of transgenic algae over-expressing A6-desatu rases and
Generation of transgenic algae over-expressing ∆ -elongase
Materials and Methods
Strains and growth conditions
P. tricornutum UTEX 646 was grown in ESAW medium (Harrison et al., 1980) at 18°C
and 20°C with moderate shaking under white fluorescent lights in constant illumination
(30 µηιοΙ and 60 µηιοΙ photons m- 2s 1) . Analysis of the wild-type and transgenic algae
have been performed during exponential and stationary growth phases.
Plasmid design and cloning
The coding sequences for ∆ 6 - desaturase from Ostreococcus tauri , OtD6 (Domergue
et al., 2005) and O.tauri ∆ 5- elongase OtElo5 (Meyer et al., 2004 ) were inserted as
Kpn-Xba and EcoRV-Sacl fragments, respectively, into pPha-T1 vector (Zaslavskaia et
al., 2000), kindly provided by Dr. P.G.Kroth, (Universitat Konstanz, Germany). The
coding region of OtD6 was used as a template to chemically synthesize (Genscript
Corporation, NJ) codon-optimized nucleotide sequence OtD6PT for expression in
P.tricornutum. This codon-optimized ∆ 6 - desaturase sequence was cloned into pPha-
T 1 vector, using EcoRV-Sacl sites. The coding sequences for ∆ 6 - desaturase from P.
tricornutum, PtD6 (Domergue et al., 2002) was inserted as BamHI -Xbal fragment into
pPha-T1 vector (Zaslavskaia et al., 2000).
Biolistic transformation
Biolistic transformation of P. tricornutum was performed according to previously
described (Zaslavskaia et al., 2000; Kroth 2007). Bombarded cells were transferred
onto ESAW agar plates containing 75 µg/ml zeocin. The zeocin plates were placed in
24 h light under fluorescent lights (50 µηιοΙ η 2 s ) and incubated at 20°C for 3 weeks.
Selected zeocin-resistant colonies were transferred to fresh zeocin plates and 2 ml
ESAW+ zeocin cultures before being transferred to liquid medium minus antibiotic for
lipid analysis.
Fatty acid analysis
Algae or yeast cells were harvested by centrifugation. Fatty acids were extracted and
methylated as described (Garces and Mancha, 1993) with minor modifications. A 15ml
aliquot of algal culture was harvested; following methylation the heptane fraction was
concentrated and re-suspended in 40 µ Ι solvent prior to injection of 1 µ Ι on to the GC
column. Methyl ester derivatives of total fatty acids extracted were analysed by GC
using an Agilent DB-225 column and identified using known standards.
Acyl-CoA profiling
Algal cells were harvested by centrifugation, frozen in liquid nitrogen and extracted
after Larson and Graham (2001), for reverse-phase LC w th either quantitative analysis
of fluorescent acyl-etheno-CoA derivatives or with electrospray ionization tandem mass
spectrometry (multi reaction monitoring) in positive ion mode For the analysis of
etheno-CoA derivatives HPLC (Agilent 1200 LC system; Phenomenex LUNA 150 2
mm C18(2) column) was performed using the methodology and gradient conditions
described previously (Larson and Graham 2001); whilst LC-MS/MS +MRM analysis
followed the methods described by Haynes et al. 2008 (Agilent 1200 LC system;
Gemini C18 column, 2 mm inner diameter, 150 mm with 5 mm particles). For the
purpose of identification and calibration, standard acyl-CoA esters with acyl chain
lengths from C14 to C20 were purchased from Sigma as free acids or lithium salts.
Lipid Profiling
The molecular species of TAGs and PLs were analysed by electrospray ionisation triple
quadrupole mass spectrometry (API 4000 QTRAP; Applied Biosystems). The
molecular species of polar lipid were defined by the presence of a head-group fragment
and the mass/charge of the intact lipid ion formed by ESI (Welti et al., 2002; Devaiah
et al., 2006 with modifications described by Xiao et al. 2010). Such tandem ESI-MS/MS
precursor and product ion scanning, based on head group fragment, do not determine
the individual fatty acyl species. Instead, polar lipids are identified at the level of class,
total acyl carbons, and total number of acyl carbon-carbon double bonds. Polar lipids
were quantified in comparison with a series of polar lipid internal standards.
Triacylglycerols (TAGs) measured after Krank et al. (2007) were defined by the
presence of one acyl fragment and the mass/charge of the ion formed from the intact
lipid (neutral loss profiling). This allows identification of one TAG acyl species and the
total acyl carbons and total number of acyl double bonds in the other two chains. The
procedure does not allow identification of the other two fatty acids individually nor the
positions (sn-1 , sn-2, or sn-3) that individual acyl chains occupy on the glycerol. TAGs
were quantified in a manner similar to the polar lipids, including background
subtraction, smoothing, integration, isotope deconvolution and comparison of sample
peaks with those of the internal standard (using LipidView, Applied Biosystems).
However, whereas polar lipids within a class exhibit similar mass spectral response
factors, the mass spectral responses of various TAG species are variable, owing to
differential ionization of individual molecular TAG species. In the data shown herein, no
response corrections were applied to the data. The data were normalized to the
internal standards tri 5:0 and t ri 9:0
Results
Generation of transgenic algae over-expressing A6-desaturases.
The native coding OtD6 and codon-optimized for expression in P. tricornutum
nucleotide sequences for O.tauri ∆ 6 - desaturase were cloned into pPha- T 1 vector,
generating expression cassettes OtD6N and OtD6Pt respectively, and the resulted
constructs were used to transform P. tricornutum.
Expression of OtD6N construct
13 zeocin resistant colonies were obtained by transformation with OtD6N and selected
for further screening. Selected colonies were transferred into liquid medium and
several positive transformants containing OtD6N were identified. We have studied the
effects of temperature and light on the production of EPA and total fatty acids in t and
transgenic P.tricornutum. Cultures were grown at different temperatures (18°C and
20°C) under constant illumination in different light intensity (25 µηιοΙ and 60 µηιοΙ
photons m- 2s 1) . GC-MS analyses have been performed during the exponential (E) and
stationary (S) phases of cell growth. Fatty acid profiling of WT and mutants showed
that palmitoleic acid (16:1 ∆ 9) , EPA (20:5 n-3), palmitic acid (16:0) and myristic acid
(14:0) were the major FAs detected in algal cells grown in both stages. Similarly to the
results obtained by Tonon et al. (Tonon 2002) from the studies of P. tricornutum (CCAP
1052/1 A) cell cultures grown at 18°C with 240 µΕ m- 2s 1 , there was decrease in the
amount of EPA and DHA as the cells of F'.tricornutum UTEXS 646 used in our study
shifted from exponential to stationary phase . Fatty acid analysis revealed that in cells
transformed with Otd6N and grown at 20°C in light intensity 25 µηιοΙ and 60 µηιοΙ
photons m- 2s 1 EPA and DHA decreased upon transition to stationary phase. However,
the levels of EPA and DHA in Otd6N cells grown at 20°C, 60 µΕ m- V in stationary
phase were higher than those of WT P. tricornutum (21 .2% of EPA and 1.8% of DHA
in Otd6N compared to 18.5% of EPA and 1.3% of DHA in WT (Table III, Fig. 1). In
contrast, we found that in transgenic Otd6N cells grown at 18°C, 25 µΕ m- 2s 1 levels of
EPA and DHA increased in stationary phase compared to exponential phase and are
significantly higher than in WT samples (30.2% of EPA and 1.8% of DHA in Otd6N
compared to 16.5% of EPA and 0.9% of DHA in WT). Fatty acids profiles from Wt and
Otd6N transgenic P. tricornutum showed no differences in ∆ 6 - unsaturated fatty acids
(GLA and SDA) composition, which were barely present.
Expression of OtD6PT construct
4 zeocin resistant colonies obtained by transformation with OtD6PT were selected to
inoculate cultures for further screening and GC-MS analysis. The same trend towards
decreasing levels of EPA and DHA in the stationary phase was observed for transgenic
Otd6Pt cells grown at different light intensity and temperatures (Table III, Fig. ) .
Recombinant cells expressed higher levels of EPA (20.8% in the stationary phase at
20°C, 60 µΕ m- V and 22.2% at 18°C, 25 µΕ m- V compared to 18.5% and 16.8% in
WT respectively). In addition to detection of higher levels of EPA w e also observed an
increase in DHA levels with minor variation between the two phases of growth (Table
III, Fig.1).
Generation of transgenic algae over-expressing OtElo5
3 zeocin resistant clones obtained by transformation with OtElo5 were identified in an
initial screen and used to inoculate cultures for further screening and GC-MS analysis.
Cultures were grown at 20°C under constant illumination in 60 µηιοΙ photons m- s .
FAMEs analysis of P. tricornutum transformed with OtElo5 have been performed during
the exponential (E) and stationary (S) phases of cell growth and revealed the presence
of DPA in the range of 2.8-4.7% in transgenic clones which was not detected in WT
cells (Table IV, Fig 2a). Levels of EPA in transformed clones were decreased to an
average of 17.7% compared to 35.9% in WT in the exponential phase of growth and to
8.2% in clones over-expressing the Elo5 gene compared to 18.5% in WT during the
stationary phase of growth. A substantial increase in DHA was observed in all 3
transgenic clones averaging 7.4% in exponential phase and 10.4% in stationary phase
compared to 2.0% and 1.3% respectively in WT. DHA accumulation has been
increased upon transition to stationary phase.
Determination of acyl-CoA pool composition
To better understand the processes of acyl desaturation in diatoms the composition of
the acyl-CoA pool was determined for the wild-type (WT) and transgenic P.
tricornutum, expressing OtElo5-elongase (Fig.3). The study of acyl-CoA profile of WT
P. tricornutum in the stationary phase of growth revealed that palmitic, palmitoleic,
stearic, oleic and EPA-CoA were the most abundant, thus demonstrating the direct
relationship between the levels of native fatty acids in the acyl-CoA pool vs the total
fatty acids. EPA-CoA represented 5.7% of the acyl-CoA pool, indicating that this level
of EPA-CoA could potentially act as an intermediate in the synthesis of DHA through
elongation to 22:5n-3 and desaturation to 22:6n-3. Only traces (<1 .0) of 22:4 n-6, 22:5
n-3 (DPA) and DHA were detected in the CoA pool of WT P. tricornutum. As can be
seen in Figure 3 , similar analysis of transgenic P. tricornutum demonstrated a
significant increase in the levels of 22:4 n-6, 22:5 n-3 (EPA) and DHA accompanying
by the decrease in EPA levels. As shown in Figure 4 , detailed analysis of the
composition of the acyl-CoA pool through different stages of cell growth revealed that
EPA and DHA were accumulating progressively from exponential to stationary phase
displaying maximum levels of 5.2% and 6.3% in stationary phase.
Profiling of TAG molecular species
In this study we identified and compared the molecular species of TAGs formed by WT
and OtElo5 transgenic P. tricornutum and investigated changes in TAG synthesis in
response to transition from exponential to stationary phase. Cultures were grown at
20°C under constant illumination in 60 µηιοΙ photons m- 2s 1 and analysed using ESI-
MS. The mass spectrum obtained from direct infusion ESI-MS of algal lipid extracts
shows that a majority of the molecular ions are observed between 750 and 950
mass/charge (m/z). We detected 26 individual TAG species in WT P. tricornutum. The
oil extracts of WT were predominantly composed of TAGs 46:1, 48:2 48:1 , 48:2, and
48:3 and 50:3, having palmitic (18:0), pa!mito!eic (16:1), and myristic (14:0) acid
substituents TAG 48:1 (16:0/16:0/16:1) and 48:2 (16:0/16:1/16:1) constitute the main
TAG molecular species that is expressed throughout the time course analysis of P.
tricornutum cells (Figs 5a and 5B). An increase in the diversity of TAG molecular
species (with as much as 29 individual TAGs) was detected from cells expressing
OtElo5 -elongase. Specifically, new TAG species, 54:8, 54:9 and 56:8 were observed
and transgenic cells show significantly higher levels of 54:7. DHA was incorporated in
TAGs 52:7, 54:7, 54:8, 54:9 and 56:8. The time course (Fig. 6) also revealed that TAGs
54:7 and 56:8 appear to have more DHA incorporated into TAGs as the ceils shift from
the exponential growth phase to the stationary phase. TAGs molecular species 52:7,
54:8 and 54:9 demonstrated more or less constant DHA proportions when cultures
were shifted from exponential to stationary phase. Levels of TAGs containing DHA
averaged 12.5% in exponential stage and 10.5% in the stationary phase.
Table III. Fatty acid composition (molar %) of WT and transgenic P. tricornutum
expressing O. tauri ∆ 6 desaturase under different growth conditions at two growth
stage, where E is the exponential and S is the stationary growth phases. Each
measurement is the average of three biological replicates.
20°C ΘΟµηιοΙ photons 20°C 25µηιοΙ photons 18°C 25µηιοΙ photons
Cell strain E S E S E S
Otd6N 14:0 6.3±1.1 5.6±1.6 11.5±0.7 7.6±1.5 13.0±1.1 10.9±1.0
16:0 16.0±0.5 21.0±1.3 12.8±0.9 16.8±1.6 15.3±0.8 16.6±1.1
16:1 28.3±1.7 36.5±1.6 32.8±0.2 30.3±1.9 35.1 ±2.1 34.4±2.5
16:3 2.5±0.2 0.9±0.2 4.0±0.6 0.9±0.1 3.6±0.0 2.7±0.2
18:0 0.5±0.0 0.7±0.0 0.3±0.0 0.4±0.0 ND ND
18:1 6.2±1.4 8.6±1.5 18.1 ±0.0 24.9±0.3 2.1±0.2 2.5±0.2
18:2n-6 1.5±0.1 0.6±0.0 ND ND 1.4±0.2 1.4±0.2
18:3 n-6 0.7±0.3 1.3±0.3 ND ND ND ND
18:4 n-3 0.8±0.1 0.8±0.1 ND 0.4±0.0 1.0±0.4 1.0±0.4
20:5 n-3 32.2±3.6 21.2±1.9 20.6±1.1 17.8±2.6 27.1 ±2.7 30.2±3.2
22:6 n-3 2.3±0.2 1.8±0.3 1.4±0.1 1.0±0.1 1.4±0.4 1.8±0.3
Others 6.89±0.6 4.3±0.6 12.2±1.8 6.0±0.2 5.7±0.4 6.2±0.6
Otd6Pt 14:0 7.0±1.4 4.9±1.0 5.6±0.2 4.9±0.2 12.8±0.1 7.4±0.4
16:0 16.3±1.3 20.2±1.5 9.5±0.3 16.8±0.7 17.0±0.9 20.4±0.2
16:1 27.1 ±4.0 38.6±3.6 24.5±0.2 33.4±7.9 28.3±1.2 35.8±2.6
16:3 2.5±0.2 1. 1±0.3 4.0±0.6 1.4±0.1 2.9±0.0 5.2±1.1
18:0 0.5±0.1 0.6±0.1 0.3±0.0 0.4±0.0 ND ND
18:1 7.8±0.2 8.7±0.4 26.9±5.4 24.9±0.3 6.0±0.9 8.5±0.9
18:2 n-6 1.1±0.2 1.1±0.1 ND ND 1.2±0.0 1.2±0.0
18:3 n-6 1.2±0.2 0.8±0.0 0.2±0.0 0.2±0.0 ND ND
18:4 n-3 1.1±0.1 1.2±0.1 0.6±0.1 0.6±0.0 1.5±0.0 1.5±0.0
20:5 n-3 33.2±1.4 20.8±3.5 27.0±4.0 16.6±2.0 25.8±0.1 22.2±1.3
22:6 n-3 1.7±0.3 1.5±0.4 1.3±0.1 1.2±0.6 1. 1±0.0 1.3±0.2
Others 9.2±0.6 4.3±0.9 12.3±1.8 5.5±3.6 7.3±0.3 3.1±0.3
WT 14:0 7.7±0.5 4.8±0.1 5.1 ±0.2 4.8±0.5 10.9±0.5 7.9±0.1
16:0 16.5±0.4 22.2±0.6 11.0±2.0 16.6±3.2 19.7±0.4 21.1±1.3
16:1 28.4±0.6 41.8±0.5 22.3±1.1 32.2±4.1 35.8±0.6 42.1 ±2.5
16:3 2.4±0.3 1.0±0.1 2.6±0.6 0.6±0.1 2.4±0.3 1.4±0.0
18:0 0.4±0.0 0.5±0.0 0.3±0.1 0.3±0.1 ND ND
18:1 3.8±0.8 7.3±0.2 28.9±1.4 25.7±4.9 6.1±0.3 8.2±0.1
18:2n-6 1.4±0.1 0.6±0.0 ND ND 1.1±0.1 0.8±0.1
18:3n-6 0.7±0.0 0.6±0.0 ND ND ND ND
18:4 n-3 0.8±0.0 1.0±0.0 0.6±0.0 0.4±0.1 1.0±0.7 0.6±0.8
20:5n-3 35.9±1.6 18.5±0.4 27.6±2.3 17.1 ±2.5 22.2±0.7 16.8±2.8
22:6n-3 2.0±0.3 1.3±0.0 1.8±0.1 1.3±0.3 0.8±0.1 0.9±0.2
Others 6.8±0.3 2.4±0.3 10.0±0.9 5.1±0.8 4.9±0.5 2.9±0.3
Table IV. Fatty acid composition (molar %) of WT and transgenic P. tricornutum
expressing Ot Elo5 during exponential (E) and stationary (S) phases. Cultures were
grown at 20°C 60 µηιοΙ m-2s-1 under constant agitation at 70 rpm. Each measurement
is the average of 3 biological replicates.
Discussion
Many marine microbes produce high levels of EPA and DHA but only few species have
the ability to partition these fatty acids into storage lipids in the form of triacylglycerols
(TAGs). The majority of algal species accumulate saturated and mono-unsaturated
fatty acids in TAGs (Harwood, 1998; Roessler, 1990b). Partitioning of LC-PUFAs into
TAGs have been observed in Parietochloris incise (Bigogno et al., 2002), the
freshwater red microalga Porphyridium omentum (Cohen et al., 2000), and marine
microalgae Nannochloropsis oculata, Phaeodactylum tricornutum, Thalassiosira
pseudonana and Pavlova lutheri, (Tonon et al., 2002). Thus these species are good
candidates for further studies, in order to understand the processes responsible for the
incorporation of LC-PUFAs into storage oils in microalgae.
At present it is generally accepted that oleaginous algae produce small quantities of
TAG under optimal growth conditions (Hu et al. 2008). Among major factors affecting
triacylglycerol accumulation and fatty acid composition in microalgae are temperature
and light intensity. Generally, it is considered that fatty acid unsaturation increases with
temperature decrease and low light favours the formation of PUFAs. For example, in
P.tricornutum UTEXS 640 optimal culture temperature for EPA production was 2 1.5 to
23°C (Yongmanitchai W. and Ward O., 1991). A temperature shift strategy has been
employed to enhance the overall n-3 PUFAs (including EPA) production because the
optimal temperature for microalgal growth is often higher than that for n-3 PUFAs
formation (Jiang and Chen, 2000). Such a phenomenon has been observed in many
different algal species including P. omentum (Springer et al., 1994), Nannochloropsis
sp. (Sukenik, 1991) and P. irregular (Stinson et al., 1991). However, Ohta et al. (1993)
observed that the optimal temperature for growth of P. purpureum also yields a
biomass with the highest EPA content. These results suggest that the effect of
temperature on cell growth and n-3 PUFA production should be carefully studied for
individual microalgal species.
Profiling of TAG species in P. tricornutum has been previously reported
(Yongmanitchai and Ward 1993; Yu et al., 2009). We observed the same predominant
fatty acids (i.e., 14:0, 16:0, 16:1 , 16:3, and 20:5) incorporated in TAGs as described in
these earlier studies. Yongmanitchai and Ward 1993 identified only 18 TAG molecular
species via reverse-phase HPLC analysis. Due to the high resolution and sensitivity of
ESI-MS, Yu et al., 2009 were able to detect twofold more species in algal oil extracts
(14 of the 18 species they detected by HPLC, at comparable percentage composition.
However, TAGs 48:7, 48:9, 48:12, and 54:10 were not detected which could be
explained by the difference in the P. tricornutum strains and culture conditions.
Example 2
Identification and characterization of new activities for PUFAs biosynthesis in
algae and plants
2.1 Identification of a ∆ 6 - desaturase from the microalga Ostreococcus RCC809
Genome of green alga Ostreococcus RCC809 was analysed with BLAST using already
known N-terminal cytochrome b5-fusion desaturases as query. This analysis revealed
the presence of several genes coding for putative PUFA desaturases. The deduced
open reading frames were used as templates to chemically synthesise (Genscript
Corporation, NJ) codon-optimised nucleotide sequences for expression in diatoms.
Functional characterization of putative Ostreococcus RCC809 ∆ 6 -desaturase in yeast.
The codon-optimised open reading frame of the putative ∆ 6 - desaturase (SEQ ID
No.s 7 to 10, hereafter designated Ost809A6) was inserted as Kpnl-Sacl fragment
behind the galactose -inducible GAL1 promoter of the yeast expression vector pYES2
(Invitrogen, NJ). Ost809A6
The S. cerevisiae strain W303-1A was transformed with plasmid DNA using a lithium
acetate method. Cultures were grown at 22°C in the presence of 2% (v/v) raffinose for
48 h , and expression of the transgene was induced by addition of galactose to 2% in
the presence of 0.5 mM of linoleic acid (LA, 18:2n-6) and 1% (w/v) tergitol NP-40
(Sigma) as described (Sayanova et al., 2001).
The predicted function of the candidate desaturase Ost809A6 (predicted to encode a
C18 ∆ -desaturase of 461 amino acids) was investigated by expression studies in S.
cerevisiae in the presence of a range of potential fatty acid substrates. Total fatty acid
methyl esters from yeast cells were then analysed by GC-FID and the identity of novel
peaks confirmed by GC-MS and co-migration with authentic standards. As shown in
Fig. 8 , expression of a synthetic ORF encoding Ost809A6, confirmed the enzymatic
capability to convert exogenously supplied substrate (a-Linolenic acid, ALA;
C18:A9,12,15) to the A6-desaturated product SDA (18:4, n-3). In the absence of
galactose, the exogenous substrate ALA is not converted to SDA. Thus, on the basis of
these results, Ost809A6 was confirmed as a D6-desaturase. The substrate selectivity
of Ost809A6 was determined by exogenously supplying equal quantities of LA and ALA
in the growth media. As it is shown in Figure 9 , Ost809A6 only recognised the n-3 fatty
acid ALA as a substrate, whereas the n-6 substrate was not desaturated. This is
distinct from a ∆ -desaturase identified from Ostreococcus tauri (Domergue et al,
2005), which showed activity towards both LA and ALA as substrates. Thus Ost809A6
is superior and distinct for the exclusive production of ∆ -desaturated n-3 fatty acids.
Yeast cultures were supplemented with different potential FA substrates (listed in Table
V) but desaturation activity of O809d6 was detected only in the presence of ALA.
2.2 Identification of putative ∆ 4 - desaturase from O809
The genome sequence of Ostreococcus RCC809 http://genome.jgi-
psf.org/OstRCC809_2/OstRCC809_2.home.html was searched with previously
functionally characterised sequences of A4-desaturases and the presence of an
apparent candidate (JGI protein ID # 40461) for a A4-desaturase was detected. The
deduced open reading frame was used as a template to chemically synthesise
(Genscript Corporation, NJ) codon-optimised nucleotide sequences for expression in
diatom P. tricornutum (SEQ ID No.s 15 to 18).
Functional characterization of putative ∆ 4 - desaturase from O809 in yeast.
The codon-optimised for expression in P. tricornutum open reading frame of the
putative ∆ 4 - desaturase was inserted as Kpnl-Sacl fragment behind the galactose -
inducible GAL1 promoter of the yeast expression vector pYES2 (Invitrogen, NJ).
As can be seen in Fig 10, galactose-dependent expression of the Ost809 protein
40461 resulted in the ∆ 4-desaturation of DPA to DHA, confirming the function of this
ORF as a C22 ∆ 4-desaturase and on this basis we designated this gene as Ost809A4.
Note that in the absence of the inducer (galactose), no DHA is detected, nor in the
absence of the Ost809A4 ORF.
2.3 Identification of a A6-elongase from Fragilariopsis cylindrus
The publically available genome sequence of the marine diatom Fragilariopsis
cylindrus (http://genome.jgi-psf.org/Fracy1/Fracy1.home.html) was analysed with
BLAST using already known ∆ -elongase sequences (such as the ∆ -elongase from
C.elegans - Beaudoin et al, 2000) as query and a candidate open reading frame
(designated Frag #177742) was used as a template to chemically synthesise
(Genscript Corporation, NJ) codon-optimised nucleotide sequence for expression in
T.pseudonana.
Functional characterization ofFc A6-elongase in transgenic yeast
Heterologous expression of Frag #177742 in S. cerevisiae was carried out exactly as
described above, with the codon-optimised ORF cloned into the yeast expression
vector pYES2. Galactose-mediated induction of this construct was used to confirm that
this ORF functioned as a ∆ 6-elongase, specifically elongating C18 ∆ 6-unsaturated
substrates such as GLA to a C20 form. As can be seen in figure 11, elongation of GLA
to 20:3 only occurs in the presence of galactose and the ORF Frag #177742. On the
basis of these results, this was redesignated FcEL06.
Table V. List of Substrates Tested:
Ost809 D6
18:2, ALA, GLA, 18:2 &18:3 , 20:4n-6 (ARA), 20:2, ERA, ETA, 22:5n-6 (DPA)
FcElo6
18:2, GLA, GLA & SDA
Ost809A4
DPA
(Substrates underlined are those which worked)
Table VI. Fatty acid composition of yeast cells expressing Ost809A6,
FcElo6 or Ost809A4 and substrate specificities of each of these
Table VII. Substrate specificity
On the basis of the identification of novel forms of the ∆ 6-desaturase (Ost809A6), ∆ 4-
desaturase (Ost809A4) and the ∆ 6-elongase (FcEL06), it is very likely that these
activities will prove useful in the heterologous reconstitution of the omega-3 long chain
polyunsaturated fatty acid biosynthetic pathway in algae and plants. For example, the
superior substrate-preference of the Ost809A6 enzyme distinguishes it from other
Ostreococcus ∆ 6-desaturases, and can be used to maximise the flux of substrate
through the n-3 pathway. Similarly, the Ost809A4 activity will prove useful in the
specific conversion of DPA to DHA in transgenic photosynthetic organisms, whilst the
FcEL06 activity provides a means by which GLA can be elongated to 20:3n-3.
Example 3
Expression of single omega-3 LC-PUFA biosynthetic genes in Pheaodactylum
tricornutum can increase the endogenous accumulation of DHA
Materials and methods
Strains and growth conditions
P. tricornutum UTEX 646 was grown in ESAW medium (Harrison et al., 1980) at 20°C
with moderate shaking under white fluorescent lights in constant illumination (100 µηιοΙ
photons m- 2s 1) . Analysis of the wild-type and transgenic algae have been performed
during stationary growth phase.
Plasmid design and cloning
The coding sequence for A6-elongase FcElo6 (protein ID 177742) was used as a
template to chemically synthesize (Genscript Corporation, NJ) a codon-optimized
nucleotide sequencea for expression in T. pseudonana. The codon-optimized
sequence was inserted as EcoRV-SacI fragments, respectively, into pPha-T1 vector
(Kroth, 2007; Zaslavskaia et al., 2000).
Results
Expression of FcElo6 resulted in increase of DHA levels up to 14-17% (Figure 13).
Example 4
Co-expression of two genes
Material and methods
Design of double-gene vector pPhOS2 and transformation cassettes
The EcoRI —Hindi 11fragment of of pPha -T1 vector containing MCS was replaced by
the synthetic sequence comprising of fcpA terminator and fcpA promoter flanked by 3
multiple cloning sites (MCSs) with unique restriction sites (Figure 14). The coding
sequences for O. tauri ∆ δ -elongase OtElo5 was inserted as Kpnl-Sacl fragment into
position 1 of pPhOS vector generating pPhOS2.1 . 1 construct. The codon optimized for
expression in P.tricornutum coding sequences for O. tauri ∆ -desaturase OtD6Pt was
inserted as BamHI- Xbal fragment into position 2 of pPhOS2.1 . 1 generating
pPhOS2.2.1 construct.
Results and Discussion
Mu!tigene expression in transgenic P. tricornutum
To facilitate the expression of multiple heterologous genes in P. tricornutum, a new
vector (designated pPhOS2- Figure 14) was constructed. This vector is based on
previously described pPha-T1 vector (Zaslavskaia et al., 2000) and contains two
multiple cloning sites (MCS) with unique restriction sites for inserting genes of interest.
Each of these MCS is flanked by the promoter and terminator regions of the FcpA gene
(Zaslavskaia et al., 2000) to promote the co-expression of two inserted genes. The
coding sequence for O. tauri ∆ δ -elongase OtElo5 was inserted into position 1 of
pPhOS2 vector and the resulting construct pPhOS2.1.1 was used to transform P.
tricornutum. Cultures were grown at 20°C and 16°C under constant illumination (60
µηιοΙ photons m 2s 1) . Multiple (5) independent zeocin-resistant colonies were obtained
and used to inoculate cultures for further GC-MS analysis. The mean levels of DHA in
analysed pPhOS2.1 .1 strains was 9.0% (Table VIII; Figure 1), similar to levels
previously observed with OtElo5 expression in pPHa-T1 , confirming the functionality of
this modified vector. The codon-optimized coding sequences for O. tauri ∆ 6-
desaturase OtD6Ptwas subsequently inserted into position 2 of construct pPhOS2.1.1 ,
generating the two-gene (plus the selectable marker gene ble) pPhOS2.2.1 vector.
This expression plasmid was introduced into P. tricornutum via biolistics and multiple
independent zeocin-resistant colonies were obtained and used to inoculate cultures for
further screening. Cultures were grown at 16 and 20°C under constant illumination (60
µηιοΙ photons m- 2s 1) . FAMEs analysis of transgenic strains expressing either single or
double gene constructs revealed a further increase in DHA levels in transgenic strains
co-expressing both OtElo5 and OtD6Pt, indicating the here-demonstrated potential for
iterative metabolic engineering in P. tricornutum for high value lipid traits (Figure 15,
Table VIII).
Table VIII. Fatty acid composition (Mol %) of wild-type (Pt_WT) and transgenic P.
tricornutum expressing pPhOS2.1 and pPhOS2.2 at 16°C and 20°C. Each
measurement is the average of 3 biological replicates (± Standard Error).
Example 5
Auxorophic growth
Material and methods
Design of double-gene vector pPhOS2 and transformation cassettes
The EcoRI —Hindi 11fragment of of pPha -T1 vector containing MCS was replaced by
the synthetic sequence comprising of fcpA terminator and fcpA promoter flanked by 3
multiple cloning sites (MCSs) with unique restriction sites (Fig. 16). The coding
sequences for O. tauri ∆ δ -elongase OtElo5 was inserted as Kpnl-Sacl fragment into
position 1 of pPhOS vector generating pPhOS2.1 . 1 construct. The codon optimized for
expression in P.tricornutum coding sequences for glucose transporters from
Physcomitrella patens (designated Ppglutl), and human erythrocytes (designated
Hsglutl), were inserted as BamHI- Xbal fragments into position 2 of pPhOS2.1.1
generating pPhOS_Ppglut and pPhOS_HSglut constructs. The resulting constructs
were used to transform P. tricornutum via biolistics.
Results
Multiple (>10) independent zeocin-resistant colonies were obtained by transformations
with these two expression cassettes and used to inoculate cultures for further GC-MS
analysis. Transgenic P. tricornutum strains expressing pPhOS_Ppglut and
pPhOS_HSglut constructs accumulating DPA and elevated levels of DHA were
selected for further analysis. (Fig. 16 and Fig. 17). The transformants were transferred
to solid medium containing 0.5% of glucose, placed in complete darkness and
monitored for growth (Fig. 18).
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Sequence listing
Nucleic acids analogous to cDNA are shown.
SEQ ID No 1 Nucleic acid sequence OtElo5
atgagcgcctccggtgcgctgctgcccgcgatcgcgtccgccgcgtacgcgtacgcgacg
tacgcctacgcctttgagtggtcgcacgcgaatggcatcgacaacgtcgacgcgcgcgag
tggatcggtgcgctgtcgttgaggctcccggcgatcgcgacgacgatgtacctgttgttc
tgcctggtcggaccgaggttgatggcgaagcgcgaggcgttcgacccgaaggggttcatg
ctggcgtacaatgcgtatcagacggcgttcaacgtcgtcgtgctcgggatgttcgcgcga
gagatctcggggctggggcagcccgtgtgggggtcaaccatgccgtggagcgatagaaaa
tcgtttaagatcctcctcggggtgtggttgcactacaacaacaaatatttggagctattg
gacactgtgttcatggttgcgcgcaagaagacgaagcagttgagcttcttgcacgtttat
catcacgccctgttgatctgggcgtggtggttggtgtgtcacttgatggccacgaacgat
tgtatcgatgcctacttcggcgcggcgtgcaactcgttcattcacatcgtgatgtactcg
tattatctcatgtcggcgctcggcattcgatgcccgtggaagcgatacatcacccaggct
caaatgctccaattcgtcattgtcttcgcgcacgccgtgttcgtgctgcgtcagaagcac
tgcccggtcacccttccttgggcgcaaatgttcgtcatgacgaacatgctcgtgctcttc
gggaacttctacctcaaggcgtactcgaacaagtcgcgcggcgacggcgcgagttccgtg
aaaccagccgagaccacgcgcgcgcccagcgtgcgacgcacgcgatctcgaaaaattgac
taa
SEQ ID No 2 Amino acid sequence OtElo5
MSASGALLPAIASAAYAYATYAYAFEWSHANGIDNVDAREWIGALSLRLPAIATT
MYLLFCLVGPRLMAKREAFDPKGFMLAYNAYQTAFNVVVLGMFAREISGLGQPVW
GSTMPWSDRKSFKILLGVWLHYNNKYLELLDTVFMVARKKTKQLSFLHVYHHALL
IWAWWLVCHLMATNDCIDAYFGAACNSFIHIVMYSYYLMSALGIRCPWKRYITQA
QMLQFVIVFAHAVFVLRQKHCPVTLPWAQMFVMTNMLVLFGNFYLKAYSNKSRGD
GASSVKPAETTRAPSVRR RSRKID*
SEQ ID No 3 OtD6 nucleic acid sequence
atgtgcgtggagacggaaaataacgatgggatccccacggtggagatcgcgttcgacggt
gagcgcgagcgggcggaggcaaacgtgaagctgtccgcggagaagatggagccggcggcg
ctggcgaagacgttcgcgaggcggtacgtcgtgatcgagggggtggagtacgatgtgacg
gattttaagcacccgggaggaacggttattttctatgcgttgtcaaacaccggggcggac
gcgacggaagcgttcaaggagtt teatcatcggtcgagaaaggcgaggaaagccttggcg
gcgctcccgtctcgaccggccaagacggccaaggtggacgacgcggagatgctccaagat
ttcgccaagtggcggaaagaattggagagagatggattcttcaagccctctccggcgcac
gtggcgtatcgcttcgccgagctcgcggcgatgtacgctctcgggacgtacctgatgtac
gctcgatacgtcgtctcctcggtgctcgtgtacgcttgctttttcggcgcccgatgcggt
tgggtgcagcacgagggcggacacagctcgctgacgggcaacatttggtgggacaagcgc
atccaggccttcacagccgggttcggtctcgccggtagcggcgacatgtggaactcgatg
cacaacaagcatcacgcgacgcctcaaaaggttcgtcacgacatggatctggacaccacc
cccgcggtggcgttcttcaacaccgcggtggaagacaatcgtccccgtggctttagcaag
tactggttgcgccttcaggcgtggaccttcatccccgtgacgtccggcttggtgctcctt
ttctggatgtttttcctccacccctccaaggctttgaagggtggcaagtacgaagagttg
gtgtggatgctcgccgcgcacgtcatccgcacgtggacgatcaaggcggtgaccggattc
accgcgatgcagtcctacggcttatttttggcgacgagctgggtgagcggctgctatctg
tttgcacacttctccacgtcgcacacgcacctggatgtggtgcccgcggacgagcatctc
tcctgggttcgatacgccgtcgatcacacgatcgacatcgatccgagtcaaggttgggtg
aactggttgatgggctacctcaactgccaagtcatccaccacctctttccgagcatgccg
cagttccgccagcccgaggtatctcgccgcttcgtcgcctttgcgaaaaagtggaacctc
aactacaaggtcatgacctacgccggtgcgtggaaggcaacgctcggaaacctcgacaac
gtgggtaagcactactacgtgcacggccaacactccggaaagacggcgtaa
SEQ ID No 4 OtD6 amino acid sequence
MCVETENNDGI P VEIAFDGERERAEANVKLSAEKMEPAALAKT FARRYVVIEGVEYDVT
DFKHPGGTVIFYALSNTGADATEAFKEFHHRSRKARKALAALPSRPAKTAKVDDAEMLQD
FAKWRKELERDGFFKPSPAHVAYRFAELAAMYALGTYLMYARYVVSSVLVYACFFGARCG
WVQHEGGHSSLTGNIWWDKRIQAFTAGFGLAGSGDMWNSMHNKHHATPQKVRHDMDLDTT
PAVAFFNTAVEDNRPRGFSKYWLRLQAWTFIPVTSGLVLLFWMFFLHPSKALKGGKYEEL
VWMLAAHVIRTWTIKAVTGFTAMQSYGLFLATSWVSGCYLFAHFSTSHTHLDVVPADEHL
SWVRYAVDHTIDIDPSQGWVNWLMGYLNCQVIHHLFPSMPQFRQPEVSRRFVAFAKKWNL
NYKVMTYAGAWKATLGNLDNVGKHYYVHGQHSGKTA*
SEQ ID No 5 OtD6Pt nucleic acid sequence optimised codon
ggtaccaagcttgatatcaccaaaatgtgtgtcgaaacggaaaacaacgatggaatccccacgg
tcgaaattgcctttgatggagaacgcgaacgcgccgaagccaacgtcaagctctccgccgaaaa
gatggaacccgccgccttggccaagaccttcgcccgtcgctacgtcgtcattgaaggtgtcgaa
tacgatgtcaccgacttcaagcacccgggaggtacggtcatcttttacgccctctccaacaccg
gagccgacgccacggaagccttcaaggaatttcaccaccgttcccgcaaggcccgtaaggccct
cgccgccttgccctcgcgcccggccaagaccgccaaggtcgacgatgccgaaatgcttcaggat
ttcgccaagtggcgtaaggaactcgaacgcgacggcttctttaagccctccccggcccacgtcg
cctaccgttttgccgaactcgccgccatgtacgcccttggaacctacctcatgtacgcccgtta
cgtcgtctcctcggtcttggtctacgcctgcttctttggtgcccgctgtggatgggtccagcac
gaaggcggacactcctcgctcaccggaaacatttggtgggataagcgtatccaagccttcacgg
ccggatttggtttggccggctccggagacatgtggaactcgatgcacaacaagcaccacgccac
cccccagaaggtccgtcacgacatggatctcgacaccacgccggccgtcgccttctttaacacc
gccgtcgaagataaccgtccccgcggattctccaagtactggcttcgtctccaagcctggacct
tcattcccgtcacgtccggtttggtcctcttgttttggatgttctttcttcacccgtcgaaggc
cctcaagggtggcaagtacgaagaattggtctggatgcttgccgcccacgtcattcgtacctgg
acgatcaaggccgtcaccggtttcacggccatgcagtcctacggcttgtttcttgccacctcct
gggtctcgggttgctacctcttcgcccacttttccacctcgcacacgcacttggatgtcgtccc
cgccgacgaacacctttcctgggtccgctacgccgtcgaccacaccattgacattgacccgtcg
cagggatgggtcaactggctcatgggttacttgaactgtcaagtcatccaccacctcttcccct
ccatgccgcagtttcgtcaacccgaagtctcgcgtcgcttcgtcgcctttgccaagaagtggaa
cttgaactacaaggtcatgacctacgccggagcctggaaggccacgcttggaaaccttgataac
gtcggaaagcactactacgtccacggccagcactcgggaaagaccgcctaagagctcggtaccc
tcgag
SEQ ID No 6 OtD6 amino acid sequence optimised codon
MCVETENNDGI P VEIAFDGERERAEANVKLSAEKMEPAALAKT FARRYVVIEGVEYDVT
DFKHPGGTVIFYALSNTGADATEAFKEFHHRSRKARKALAALPSRPAKTAKVDDAEMLQD
FAKWRKELERDGFFKPSPAHVAYRFAELAAMYALGTYLMYARYVVSSVLVYACFFGARCG
WVQHEGGHSSLTGNIWWDKRIQAFTAGFGLAGSGDMWNSMHNKHHATPQKVRHDMDLDTT
PAVAFFNTAVEDNRPRGFSKYWLRLQAWTFIPVTSGLVLLFWMFFLHPSKALKGGKYEEL
VWMLAAHVIRTWTIKAVTGFTAMQSYGLFLATSWVSGCYLFAHFSTSHTHLDVVPADEHL
SWVRYAVDHTIDIDPSQGWVNWLMGYLNCQVIHHLFPSMPQFRQPEVSRRFVAFAKKWNL
NYKVMTYAGAWKATLGNLDNVGKHYYVHGQHSGKTA
SEQ ID No 7 A6-desaturase nucleic acid from Ostreococcus RCC809
atgcgcgtcgaaacggaggacgacaacgttccgacggtcaccgtcggactgtcggaggag
agcgacgggatgaagggggcgagaaaccccggggcgcgggcgtggaaatcgacgctcgag
ccgcacgcggtggccaagtcgttcgatcgacggtgggtcaaggttgacggcgtcgagtac
gacgtcacggattttaagcatccgggtggatctgtgatttattacatgctgtcgaacacc
ggagcggacgcgacggaggcgttcaaagagtt teattatcggtcgaaaaaggcgagaaag
gcgttggcggcgttgccgcagcgcgagccggaggacgcgtcgccagtggaagacgcgaat
atgttgaaggatttcgcgaaatggcgcaaagatttggagcgcgagggtttctttaaaccg
tcgccggcgcacgtggcgtacagattcgcggaactcgcggccatgttcgcgctcgggacg
gcgttgatgtacgctcgatggcacgccacctcagtcttcgtcaccgcgtgctttttcggc
gcgcggtgcggttgggtgcaacacgagggtggtcacagctcgctgacggggagcatttgg
tgggacaagcgaatccaagcgttcaccgccggtttcggattagcatcgagcggcgacatg
tggaacctcatgcacaacaagcaccacgccactccgcaaaaggtgcgacacgacatggac
ctcgacaccacgccggcggtggccttcttcaacactgcggtcgaggaaaaccgtccgcgc
aagttcagtaagttatggttgcgcgtgcaggcgtggacgttcgtcccggtcacctctggt
ttggtgttgctcgcctggatgtacctcttgcatccgagacacattgctcgccgtaaaaac
tacgaagaggctgcgtggatcgtcgccgcgcacgtcatccgcacgtcggtcatcaaagcc
gtgaccggttactcctggatcacgtgctacggtttgttcttgtccaccatgtgggtgagc
ggctgctacctctttgcgcacttctccacgtctcacacgcacctcgacgtcgttccgagc
gataagcatctctcttgggtgcgatacgccgtcgaccacaccatcgacatcgacccgagc
aagagcgtcgtcaactggttgatgggttacctgaactgccaggtcatccatcacttgttt
ccggacatgcctcagttccgtcagcccgaagtctctcgccgcttcgtctcctttgcgaaa
aagtggaacctcaattacaaggtcatgagctactacggcgcgtggaaggccaccttcggt
aacttgaacgaggtcggcaagcactattacatccaaggttctcaaatcacgaagaagacg
gtgtaa
SEQ ID No 8 A6-desaturase amino acid from Ostreococcus RCC809
MRVETEDDNVPTVTVGLSEESDGMKGARNPGARAWKSTLEPHAVAKSFDRRWVKVDGVEYDVTD
FKHPGGSVIYYMLSNTGADATEAFKEFHYRSKKARKALAALPQREPEDASPVEDANMLKDFAKW
RKDLEREGFFKPSPAHVAYRFAELAAMFALGTALMYARWHATSVFVTACFFGARCGWVQHEGGH
SSLTGSIWWDKRIQAFTAGFGLASSGDMWNLMHNKHHATPQKVRHDMDLDTTPAVAFFNTAVEE
NRPRKFSKLWLRVQAWTFVPVTSGLVLLAWMYLLHPRHIARRKNYEEAAWIVAAHVIRTSVIKA
VTGYSWITCYGLFLSTMWVSGCYLFAHFSTSHTHLDVVPSDKHLSWVRYAVDHTIDIDPSKSVV
NWLMGYLNCQVIHHLFPDMPQFRQPEVSRRFVSFAKKWNLNYKVMSYYGAWKATFGNLNEVGKH
YYIQGSQITKKTV
SEQ ID No 9 A6-desaturase (Ost809A6) nucleic acid from Ostreococcus RCC809
codon optimised for expression in T.pseudonana
atgcgtgtggaaaccgaagacgataatgtgccaactgttactgtgggattgtcagaggagtccg
atggaatgaagggagcaaggaaccccggagcacgtgcttggaagtcgacgttggagccgcacgc
cgtggcaaagtcattcgatcgtaggtgggttaaggttgacggagtcgaatacgacgtaactgat
ttcaagcatcccggaggatcagttatctactatatgctttctaacaccggagctgatgccactg
aggctttcaaggaatttcactatcgtagtaagaaggccaggaaggcacttgctgccctcccaca
acgtgagcctgaagacgcttcgccagtcgaggatgccaatatgctcaaggacttcgcaaagtgg
cgtaaggatttggagagggaaggattctttaagccaagtcctgctcacgtggcctaccgtttcg
ccgaactcgcagctatgtttgctttgggaactgcccttatgtatgcacgttggcatgctacgtc
tgtcttcgtaacagcctgtttctttggagcaaggtgtggatgggtgcaacacgagggaggacat
tcttccttgaccggatccatctggtgggataagcgtattcaggcattcactgctggatttggac
ttgccagttcgggagacatgtggaacctcatgcacaataagcaccatgcaacgccacaaaaagt
taggcatgatatggacctcgataccactcctgcagtggctttctttaacacagctgttgaggaa
aatcgtcctaggaagttctctaagttgtggcttcgtgtccaggcctggacctttgtgcccgtta
cttccggattggtactcttggcatggatgtaccttctccacccgcgtcatatcgctcgtaggaa
gaactatgaggaagccgcatggattgtggctgcccatgttatcaggacctccgtcattaaggct
gtaacgggatacagttggatcacatgttatggactcttcttgtcgactatgtgggtctcaggat
gctacctcttcgctcacttttcaacgtctcacacacatttggacgtggttccatctgataagca
cctttcctgggtgcgttacgccgttgatcataccatcgacattgatccttccaagagtgtcgta
aactggctcatgggatatttgaactgtcaggttatccaccatttgttccccgacatgccgcaat
ttcgtcagcccgaagtcagtcgtaggttcgtatcgtttgccaagaagtggaaccttaattacaa
ggtcatgtcttactatggagcctggaaggcaaccttcggaaatctcaacgaagtcggaaagcac
tactacatccaaggaagtcaaatcacaaagaagacggtttag
SEQ ID No 10 A6-desaturase amino acid from Ostreococcus RCC809 codon optimised
MRVETEDDNVPTVTVGLSEESDGMKGARNPGARAWKSTLEPHAVAKSFDRRWVKVDGVEY
DVTDFKHPGGSVIYYMLSNTGADATEAFKEFHYRSKKARKALAALPQREPEDASPVEDAN
MLKDFAKWRKDLEREGFFKPSPAHVAYRFAELAAMFALGTALMYARWHATSVFVTACFFG
ARCGWVQHEGGHSSLTGSIWWDKRIQAFTAGFGLASSGDMWNLMHNKHHATPQKVRHDMD
LDTTPAVAFFNTAVEENRPRKFSKLWLRVQAWTFVPVTSGLVLLAWMYLLHPRHIARRKN
YEEAAWIVAAHVIRTSVIKAVTGYSWITCYGLFLSTMWVSGCYLFAHFSTSHTHLDVVPS
DKHLSWVRYAVDHTIDIDPSKSVVNWLMGYLNCQVIHHLFPDMPQFRQPEVSRRFVSFAK
KWNLNYKVMSYYGAWKAT FGNLNEVGKHYY IQGSQITKKTV
SEQ No. 11 A4-desaturase from E. huxleyi (EhD4) codon-optimized for expression in
Arabidopsis
atgggaggcgccggcgcgagcgaggctgaacggcccaagtggaccacgatccacgggcggcacg
tcgatgtgtcaaagttccgccacccgggtgggaacatcatcgagctcttctatggcatggactc
gacgagcgcgttcgagcagttccacggccaccacaagggcgcgtggaagatgctcaaggcgctg
ccgaccaaggaggtcgaccccgccgacgtgccgcagcagccgcaggagcacgttgccgagatga
cgcggctgatgacgtcgtggcgcgagcgcggcctctttaagccgcgccccgtcgcctcgggcat
ctacggtctcgccgtcgtcgctgccatcgtcgcgtgcatcgcctgcgcgccgcacgcgccggtg
ctgagcgggatcgggcteggcagetgctgggcgcagtgcggcttcctgcagcacatgggcgggc
accgcgagtggggggtgcggtactccttcctcctgcagcacttcttcgagggcctcctcaaggg
cgggtccgcctcgtggtggcgcaaccgccacaacaagcatcacgcaaagactaacgtgctcggc
gaggacggcgacctgcggacgactcccttcttcgcctgggacccgacgctcgccaagaaggttc
cagactggtcgctcaagacgcaggccttcaccttcctccccgccctcggagcgtacgtctttgt
ctttgccttcacgatccgcaagtatgccgtcgtcaagaagctctggcacgagctcgcactcatg
atcgcgcactacgcgatgttctactacgcgctgcagctcgccggtgcgtcgctcggcagcggcc
tcgccttttactgcaccggctacgcctggcaaggcatctacctcggcttcttcttcggcctgtc
ccacttcgcggtcgagcgagtcccctccaccgccacctggctcgagtcgtccatgatcggcacc
gtcgactggggaggctcctccgccttttgcggctacgtctccggcttcctcaacatccagatcg
agcaccacatggcgccgcagatgccgatggagaacctgcgccagatccgcgccgactgcaaggc
gagcgcggagaagctcgggcttccctatcgcgagctctccttcgccggcgcggtcaagctgatg
atggtcggcctctggcgcacggggagggacgagctgcagctgcgctccgacaggcgcaagtact
cgcgcacccaggcctacatggcggccgcctcggcggtggtggagaacctcaaggcggactag
SEQ No. 12 A4-desaturases from E. huxleyi codon-optimized for expression in
Arabidopsis
MGNGNLPASTAQLKSTSKPQQQHEHRTISKSELAQHNTPKSAWCAVHSTPATDPSHSNNKQHAH
LVLDITDFASRHPGGDLILLASGKDASVLFETYHPRGVPTSLIQKLQIGVMEEEAFRDSFYSWT
DSDFYTVLKRRVVERLEERGLDRRGSKEIWIKALFLLVGFWYCLYKMYTTSDIDQYGIAIAYSI
GMGTFAAFIGTCIQHDGNHGAFAQNKLLNKLAGWTLDMIGASAFTWELQHMLGHHPYTNVLDGV
EEERKERGEDVALEEKDQESDPDVFSSFPLMRMHPHHTTSWYHKYQHLYAPPLFALMTLAKVFQ
QDFEVATSGRLYHIDANVRYGSVWNVMRFWAMKVITMGYMMGLPIYFHGVLRGVGLFVIGHLAC
GELLATMFIVNHVIEGVSYGTKDLVGGASHGDEKKIVKPTTVLGDTPMEKTREEALKSNSNNNK
KKGEKNSVPSVPFNDWAAVQCQTSVNWSPGSWFWNHFSGGLSHQIEHHLFPSICHTNYCHIQDV
VESTCAEYGVPYQSESNLFVAYGKMISHLKFLGKAKCE*
SEQ ID No. 13 D4-desaturase from Thalassiosira pseudonana nucleic acid
atgggcaacggcaacctcccagcatccaccgcacagctcaagtccacctcgaagccccagcagc
aacatgagcatcgcaccatctccaagtccgagctcgcccaacacaacacgcccaaatcagcatg
gtgtgccgtccactccactcccgccaccgacccatcccactccaacaacaaacaacacgcacac
ctagtcctcgacattaccgactttgcgtcccgccatccagggggagacctcatcctcctcgctt
ccggcaaagacgcctcggtgctgtttgaaacataccatccacgtggagttccgacgtctctcat
tcaaaagctgcagattggagtgatggaggaggaggcgtttcgggattcgttttacagttggact
gattctgacttttatactgtgttgaagaggagggttgtggagcggttggaggagagggggttgg
acaggaggggatcgaaagagatttggatcaaggctttgttcttgttggttggattttggtactg
tttgtacaagatgtatactacgtcggatattgatcagtacggtattgccattgcctattctatt
ggaatgggaacctttgcggcattcatcggcacgtgtattcaacacgatggaaatcacggtgcat
tcgctcagaacaagttactcaacaagttggctgggtggacgttggatatgattggtgcgagtgc
gtttacgtgggagcttcagcacatgctggggcatcatccatatacgaatgtgttggatggggtg
gaggaggagaggaaggagaggggggaggatgttgctttggaagaaaaggatcaggaatcagatc
cagacgtattctcctccttccctctcatgagaatgcatccccaccatacaacctcatggtatca
taaataccaacacctctacgctccacccctctttgcattgatgacacttgccaaagtattccaa
caggattttgaagttgccacatccggacgattatatcatattgatgccaatgtacgttatggtt
cggtatggaatgtcatgaggttttgggctatgaaggtcattacgatgggatatatgatgggatt
accaatctactttcatggagtactgaggggagttggattgtttgttattgggcatttggcgtgt
ggagagttgttggcgacgatgtttattgtgaatcacgtcattgagggtgtgagttatggaacga
aggatttggttggtggtgcgagtcatggagatgagaagaagattgtcaagccaacgactgtatt
gggagatacaccaatggaaaagactcgcgaggaggcattgaaaagcaacagcaataacaacaag
aagaagggagagaagaactcggtaccatccgttccattcaacgactgggcagcagtccaatgcc
agacctccgtgaattggtctccaggctcatggttctggaatcacttttctgggggactctctca
tcagattgagcatcacttgttccccagcatttgtcatacaaactactgtcatatccaggatgtt
gtggagagtacgtgtgctgagtacggagttccgtatcagagtgagagtaatttgtttgttgctt
atggaaagatgattagtcatttgaagtttttgggtaaagccaagtgtgagtag
SEQ ID No. 14 D4-desaturase from Thalassiosira pseudonana amino acid acid
MGGAGASEAERPKWTTIHGRHVDVSKFRHPGGNI IELFYGMDSTSAFEQFHGHHKGAWKM
LKALPTKEVDPADVPQQPQEHVAEMTRLMTSWRERGLFKPRPVASGIYGLAVVAAIVACI
ACAPHAPVLSGIGLGSCWAQCGFLQHMGGHREWGVRYSFLLQHFFEGLLKGGSASWWRNR
HNKHHAKTNVLGEDGDLRTTPFFAWDPTLAKKVPDWSLKTQAFT FLPALGAYVFVFAFTI
RKYAVVKKLWHELALMIAHYAMFYYALQLAGASLGSGLAFYCTGYAWQGIYLGFFFGLSH
FAVERVPSTATWLESSMIGTVDWGGSSAFCGYVSGFLNIQIEHHMAPQMPMENLRQIRAD
CKASAEKLGLPYRELSFAGAVKLMMVGLWRTGRDELQLRSDRRKYSRTQAYMAAASAVVE
NLKAD*
SEQ ID No. 15 A4-desaturase Ostreococcus RCC809 nucleic acid
atgccgacgactcgatcgcgcgcgcgcgtgacgacgccccctcgcgagacgccgacgagagcga
acaccgtcgccgcgctcgatcccgagcgcaagtacacgcgcattcgcggcgtcgtgtacgacgt
cacggatttcgccagccgtcatccgggtggcgcgcaattgttatcgctgtgcgtggggagagac
gccaccatcctggtggagagtcatcaccttcgtccggaggtggtgcaaaagtacctgaagacgc
ttcccgtggtggagggcgcggcgggggcgttcgggcccgaggagacgtttccgaaaccgctcga
ctcggatttgtaccgaaagattcaggggcgcgttcgtaaagagatcgtcgaaccgttgaagatg
acgcgcggacgcgagccgcacgggcgaggctggtgcgtgttggacgccggggtggtgttggctt
tcttcgcgttcgcgttgggagtctattggaagacgccgacggtggcgacggggtgcctgttggg
gctcgccgggtactggagcggcaccggattgcaacacacggcgaaccacggtggattggcgaag
agtgggttttggaatcagttttggggatggctcgggaacgacgtcgccatcgggaagagctcgg
tggagtggagatatcatcacatggtgagccaccactcgtattgcaacgacgcggacctcgatca
agacgtgtacaccgcgctgccgcttcttcgtttggacccgtcccaggagttgaagtggttccac
cgctaccaagcgttctacgcgccgctgatgtggccgatgttgtggctcgccgcgcagtttggcg
acgcgcaaaatattttagtggataaggcgtctccgggcgtcgagtacaagggcctcatgaagct
cgaagtcgcgctgtacgttctcggaaagtttttgcattttagcttgttgctcggcgtaccggcc
tacttgcacgggtttgcgaacgccatcgtgccgttcatcgcgtacggtgcgttcggttcgttcg
tcctgtgctggtttttcatcgtcagtcacaacttggaggcgttgaccccaatcaatctgagcaa
atccacgaagaatgactggggcgcgtggcaaatcgaaacttccgcgtcctggggcaacggcttc
tggagctttttctccggcgggttgaatttgcaaatcgagcaccacttgttcccgggttgcgcgc
acaacttgtacccgaagatggttcccatcatcaaggaagagtgcgaaaaggctggcgtcacgta
caccggttacggtgggtactttggtctccttcccatcactcgggacatgttcgcgtacttgtac
aaaatgggccgacaaagcaaaaagtcggcgtaa
SEQ ID No. 16 A4-desaturase Ostreococcus RCC809 amino acid
MPTTRSRARVTTPPRETPTRANTVAALDPERKYTRIRGVVYDVTDFASRHPGGAQLLSLCVGRD
ATILVESHHLRPEVVQKYLKTLPVVEGAAGAFGPEETFPKPLDSDLYRKIQGRVRKEIVEPLKM
TRGREPHGRGWCVLDAGVVLAFFAFALGVYWKTPTVATGCLLGLAGYWSGTGLQHTANHGGLAK
SGFWNQFWGWLGNDVAIGKSSVEWRYHHMVSHHSYCNDADLDQDVYTALPLLRLDPSQELKWFH
RYQAFYAPLMWPMLWLAAQFGDAQNILVDKASPGVEYKGLMKLEVALYVLGKFLHFSLLLGVPA
YLHGFANAIVPFIAYGAFGSFVLCWFFIVSHNLEALTPINLSKSTKNDWGAWQIETSASWGNGF
WSFFSGGLNLQIEHHLFPGCAHNLYPKMVPIIKEECEKAGVTYTGYGGYFGLLPITRDMFAYLY
KMGRQSKKSA*
SEQ ID No. 17 A4-desaturase Ostreococcus RCC809 nucleic acid codon optimised
acid for expression in Pt
ggatccggtaccaagcttgatatcaccaaaatgccaactactcgttctcgtgctcgtgttacta
ctccacctcgtgaaactcctactcgtgctaatactgttgctgctttagatccagaacgtaaata
tacacgtattcgaggtgttgtatatgatgttactgattttgctagtcgacatccaggtggtgca
caattattatctttatgtgttggtcgtgatgctacaattttagtagaatcacatcatttacgac
cagaagttgtacaaaaatatttaaaaacattacctgttgtagaaggtgctgctggtgcatttgg
tccagaagaaacttttccaaaacctttagatagtgatttatatcgtaaaattcaaggtcgtgtt
cgaaaagaaattgtagaaccattaaaaatgacacgtggtcgagaacctcatggtcgtggttggt
gtgttttagatgctggtgttgtattagctttctttgcttttgcattaggtgtttattggaaaac
accaactgtagctactggttgtttattaggtttagcaggttattggtctggtacaggtttacaa
catactgctaatcatggtggtttagcaaaatcaggttttggaatcaattttggggttggttagg
aaatgatgttgctattggtaaatcaagtgtagaatggcgttatcatcatatggtttcacatcat
agttattgtaatgatgctgatttagatcaagatgtttatacagcattaccattattacgtttag
atccttcacaagaattaaaatggtttcatcgttatcaagcattttatgcacctttaatgtggcc
tatgttatggttagctgcacaatttggtgatgctcaaaatattttagttgataaagcaagtcca
ggtgtagaatataaaggtttaatgaaattagaagttgctttatatgtattaggaaaattttta
catttttctttattattaggtgttcctgcatatttacatggttttgctaatgcaattgtaccat
ttattgcttatggtgcatttggttcatttgttttatgttggtttttcattgtaagtcataattt
agaagcattaacaccaattaatttatctaaatcaactaaaaatgattggggtgcttggcaaatt
gaaactagtgcatcttggggtaatggtttttggtcatttttctcaggtggtttaaatttacaaa
ttgaacatcatttatttcctggttgtgctcataatttatatccaaaaatggttcctattattaa
agaagaatgtgaaaaagcaggtgttacatatactggttatggtggttattttggtttattacca
attactcgtgatatgtttgcttatttatataaaatgggtcgtcaatctaaaaaatctgcttaag
agctcggtaccctcgagtctaga
SEQ ID No. 18 A4-desaturase Ostreococcus RCC809 amino acid codon optimised
acid for expression in Pt
MPTTRSRARVTTPPRETPTRANTVAALDPERKYTRIRGVVYDVTDFASRHPGGAQLLSLCVGRD
ATILVESHHLRPEVVQKYLKTLPVVEGAAGAFGPEETFPKPLDSDLYRKIQGRVRKEIVEPLKM
TRGREPHGRGWCVLDAGVVLAFFAFALGVYWKTPTVATGCLLGLAGYWSGTGLQHTANHGGLAK
SGFWNQFWGWLGNDVAIGKSSVEWRYHHMVSHHSYCNDADLDQDVYTALPLLRLDPSQELKWFH
RYQAFYAPLMWPMLWLAAQFGDAQNILVDKASPGVEYKGLMKLEVALYVLGKFLHFSLLLGVPA
YLHGFANAIVPFIAYGAFGSFVLCWFFIVSHNLEALTPINLSKSTKNDWGAWQIETSASWGNGF
WSFFSGGLNLQIEHHLFPGCAHNLYPKMVPIIKEECEKAGVTYTGYGGY FGLLPITRDMFAYLY
KMGRQSKKSA*
SEQ ID No. 19 ∆ -elongase from Fragilariopsis cylindrus nucleic acid
ccatggggtaccgatatcaccaaaatggacgagtacaaagcaactcttgaatctgt
tggggatgctatcatccaatgggcagatcctgaaagtcagttcaccgggtt caeca
agggatggttcttgacagatttcacatctgcgtttagtattgcacttgtatacgtc
ttatttgtcatcattggttctcaagtgatgaaagtcttacctgctattgatccgta
cccaatcaagtttttttacaatgtatcacaaattatgctgtgtgcttacatgacga
ttgaagcatgtctgttagcgtaccgtaacggatacactatcatgccatgtgtcgga
tacaatagagatgatccagcaattggaaatcttttatggttattttatgtttcaaa
agtttgggatttttgggataccatctttatcgttttggggaagaagtggagacaac
tttctttccttcacgtttaccatcataccaccatctttttgttctactggcttaac
gcgaatgtcttttatgatggtgatatttatcttaccattgctctgaatggtttcat
ccatactgttatgtacacatactactttatctgtatgcatactaaagacaagaaaa
ctggaaaatcgcttcctatctggtggaaatcatctttgactttgttgcaattgttt
cagttcattaccatgatgtcacagggcttataccttatcatttttggttgtgaatc
actttctatccgagtcactgcgacatacgttgtttacatattgtcacttttctttt
tgtttgcgcaattcttcgttgcatcttacatgcaacctaagaaatcgaagactgcc
taagagctcggtaccttaattaa
SEQ ID No. 20 A6-elongase from Fragilariopsis cylindrus amino acid
MDEYKATLESVGDAI IQWADPESQFTGFTKGWFLTDFTSAFSIALVYVLFVI IGSQVMKVL PAI
DPYPIKFFYNVSQIMLCAYMTIEACLLAYRNGYTIMPCVGYNRDDPAIGNLLWLFYVSKVWDFW
D IFIVLGKKWRQLSFLHVYHHTTI FLFYWLNANVFYDGDIYLTIALNGFIHTVMYTYYFICMH
TKDKKTGKSLPIWWKSSLTLLQLFQFITMMSQGLYLII FGCESLSIRVTATYVVYILSLFFLFA
QFFVASYMQPKKSKTA
SEQ ID No. 2 1 ∆ δ-desurase from Fragilariopsis cylindrus nucleic acid
1 ATGGCACCCGACGCCGATCACAAGCTGAGACAGCGCCGTCTAAAAGGCGACGAAGTTTGT
61 ATCGATGGAAT TC TGA TCATCCTTCGAGCATCCGGGTGGTGA C TC AC
121 GT TTTGGTGGAAACGATGCAACAATTCAGTACAAAAT GATTCACCCGT CCAT CCACG
181 AAGCATTTAGAAAAAAT GAAGGTAGTTGGT AAGTTCCAGACT CT CTCAGAAT C AA
241 TGGGATACACCCTTCGAACGTGAAATGAAACGTGAGGTATTTAAAATTGTACGACGTGGA
301 CAAGAATTTGGTACAAATGGATATTTTTTCCGTGCCATTTCGTATATTGCTATGTTTTTT
361 TATCTGC AT TTTATGGATGC AGAATCTTCCT C CGTT GCCATCGT T CGGGATT
421 AGTATGGGATTGATTGGACTGAATGTCCAGCATGATGCGAACCACGGAGCTGCATCGAAA
481 AAAGTGTGGGTGAATGACCTCCTAGGATTGGGAGCAGACTTTATCGGAGGATCGAAATGG
541 TTGTGGATGGAAAAAC TTGGACGCATCATGCTTTT C AACCATCGAGAAAAGGATCC
601 GATGGGTTAGCAGCGGAACCTTTCCTATTGTTCAACGACTACGACTTGTCGAGTTCCAAA
661 CGTGCTGGATATCATGCATACCAAGGAATTTATTTAGTCCTATTATTGTGTGGGTATTGG
721 CTTTCGGCAATTATTGATATACCTGTAATTTGGAATCTACAAGATCGTGGTGCCCTTACG
781 GTAGGAATCCAGCTGGATAACGATTGGATTGCTAGTCGAAGAAAGTACGCGGTTAGTCTT
841 CGAATCTTATACCTCTTTTGTAACATCGTCGTTCCTCTCTATAACAATTTCTCCTGGACA
901 ACCGTGAGTCATATCAATGTAATGGGAATTTGTGGTAGCCTTACATTAGGACTACTTTTT
961 ACCTTGTCG CAC ATTTTGAGAATGTAGATCGAGATCCT CC ATCTGAACTT AATGAA
1021 ACAGAAGAACCTGTTTGCTGGTTCAAATCTCAAGTAGAAACTTCTTCAACATACGGGGGC
1081 ATGATATCCGGATGGTTAACCGGCGGATTAAACTTTCAGGTTGAGCACCATTTATTCCCG
1141 AGAATGTCTAGTGCTTGGTATCCATTTATTGCACCAAAAGTTCGTGAAATTTGCAAAAAG
12 01 CACGGAGTTCGTT CGT TACT TCCATGGTTGTTGCAAAAT TGT TTCGACGTTGAAG
12 61 TACACCCACGAGGTTGGTGTCGGCTCACATTGGAAGGATAATCCTTTTAAGGGTGAAATG
1321 TAG
SEQ ID No. 22 ∆ δ-desurase from Fragilariopsis cylindrus amino acid
1 MAPDADHKLRQRRLKGDEVCIDGIIYDISSFEHPGGDTINVFGGNDATIQYKMIHPYHTT
61 KHLEKMKWGKVPDYYSEYKWDTPFEREMKREVFKIVRRGQEFGTNGYFFRAISYIAMFF
121 YLQYLWMQESSYTLAIVYGISMGLIGLNVQHDANHGAASKKVWWDLLGLGADFIGGSKW
181 LWMEKHWTHHAFTNHREKDPDGLAAEPFLLFNDYDLSSSKRAGYHAYQGIYLVLLLCGYW
241 LSAIIDIPVIWNLQDRGALTVGIQLDNDWIASRRKYAVSLRILYLFCNIWPLYNNFSWT
301 TVSHINVMGICGSLTLGLLFTLSHNFENVDRDPTNLNLNETEEPVCWFKSQVETSSTYGG
361 MISGWLTGGLNFQVEHHLFPRMSSAWYPFIAPKVREICKKHGVRYVYYPWLLQNMYSTLK
421 YTHEVGVGSHWKDNPFKGEM-
SEQ ID No. 23 P. patens PpHUPI L codon-optimised for expression in Phaeodactylum
tricornutum
1
ATGGCAGGGGGGGGTGTCGTTACGGCGGGGGAGATCAAGCACTACCCCGGCCGAACAACC
61
TTCTTTGTGATTATGGTCTGTATAGTGGCGGCATCCGGAGGTCTCATGTTCGGATACGAT
121
GTCGGAATTTCAGGGGGTGTCACGTCTATGGACGAATTTTTGGCGAAATTTTTTCCTGCG
181
GTGTTGGCGAAGAAGCGAGCAGAGGCAGCTTCGGAGAGCGCCTACTGCAAGTATGATGAC
241
CAGAAGCTGCAAGCCTTCACATCGTCGCTGTACATTTCCGCACTCGTGTCGACATTCTTC
301
TCGTCGTACACCACCAGGCACTACGGCCGTAAATTTACCATGCTCATAGCTGGTTTCGCC
361
TTCTGCTTCGGCGTCATCTTCACCGCCGCTGCGCAAGAAATCATCATGCTAATCATAGGG
421
CGCGTCCTCCTGGGTTGGGGTGTCGGATTCGCTAACCAGGCTGTTCCGTTGTACCTCTCC
481
GAAATGGCACCCTCCAAGTGGCGAGGTGCGCTCAACATCCTCTTCCAATTGGCGGTGACC
541
ATTGGCATCCTGTTCGCCAGTCTCGTGAACTACGGCACAGAGAAGATGGCTCGCAACGGG
601
TGGCGTGTTTCCCTCGCCATCGCCGGCCTGCCTGCGATCTTCATCACCCTCGGAGGATTA
661
CTCCTGCCAGACACACCGAATTCCCTCGTGCAACGCGGCAAGCACGAGAGCGCCCGCCAG
721
GTCCTACGCAGGATTCGTGGCGTCGACAACATTGAGGAAGAGTTCGACGACATCCTCATT
781
GCCAGTAACGAAGCCGCCTCCGTGAAGCACCCCTTCCGCAATATCTTGAAACGCCGCAAC
841
CGCCCTCAGCTGGTCATCTCCATGGCTCTTCAGTTTTTCCAGCAATTCACTGGAATTAAT
901
GCTATTATGTTTTACGCGCCTGTCTTGTTCCAGACGCTGGGATTCGGGAGTTCCGCTTCA
961
CTTTACTCTGCTGTCATCGTTGGAGCCGTGAATGTGCTGGCCACTTGCGTCGCTATCGCT
1021
GTTGTGGATCGATTCGGTCGACGATGGTTGCTCTTGGAAGCTTGCATCCAAATGTTCTTA
1081
GCACAGACGGCGATTGCAATTATCCTGGCGGCGGGATTGAAGGGGACCGAGATGCCGGAG
1141
TATCTGGGATGGATCGCGGTGGTATTGATTTGCGTGTACGTGTCTTCTTTCGCGTGGTCT
1201
TGGGGTCCACTTGGATGGTTGATTCCAAGTGAGATTTTCCCCTTGGAGACGCGTTCAGCA
1261
GGGCAAGCCATCACGGTGTCGACCAACATGGTCTTCACCTTCCTCATCGCGCAAGTGTTC
1321
CTGTCAATGTTGTGCGCGTTCAAGTGGGGCATCTTCCTCTTCTTCGCCGCGTGGGTGGTG
1381
GTGATGTTCCTTTTTACGTACTTTTTAATTCCCGAGACGAAGGGCATCCCCATCGAGGAG
1441
ATGGATCTCGTGTGGACCAAGCACTGGTTCTGGAAGCGCTACGTCCCCTACCCTGAGACT
1501
CTCGCTCACACCAGCGGCATCCCCATGGGAGATATGAAGGTCAGCAAGCTGGAGAATGGC
15 61 TCCGCAAATGGCCACAAACTGTAA
SEQ ID No. 24 Deduced polypeptide sequence of PpHUPlL
1 MAGGGVVTAGEIKHYPGRTTFFVIMVCIVAASGGLMFGYDVGISGGVTSMDEFLAKFFPA
61
VLAKKRAEAASESAYCKYDDQKLQAFTSSLYISALVSTFFSSYTTRHYGRKFTMLIAGFA
121
FCFGVIFTAAAQEIIMLIIGRVLLGWGVGFANQAVPLYLSEMAPSKWRGALNILFQLAVT
181
IGILFASLVNYGTEKMARNGWRVSLAIAGLPAIFITLGGLLLPDTPNSLVQRGKHESARQ
241
VLRRIRGVDNIEEEFDDILIASNEAASVKHPFRNILKRRNRPQLVISMALQFFQQFTGIN
301
AIMFYAPVLFQTLGFGSSASLYSAVIVGAVNVLATCVAIAVVDRFGRRWLLLEACIQMFL
361
AQTAIAI ILAAGLKGTEMPEYLGWIAVVLICVYVSSFAWSWGPLGWLIPSEI FPLETRSA
421
GQAITVSTNMVFT FLIAQVFLSMLCAFKWGIFLFFAAWVVVMFLFTYFLIPETKGIPIEE
481 MDLVWTKHWFWKRYVPYPETLAHTSGIPMGDMKVSKLENGSANGHKL-
SEQ ID No. 25 Homo sapiens HsGLUTl codon-optimi sed for expres sion i n
Phaeodactylum tricornutum
1
ATGGAGCCCAGCAGCAAGAAGCTGACGGGTCGCCTCATGCTGGCTGTGGGAGGAGCAGTG
61
CTTGGCTCCCTGCAGTTTGGCTACAACACTGGAGTCATCAATGCCCCCCAGAAGGTGATC
121
GAGGAGTTCTACAACCAGACATGGGTCCACCGCTATGGGGAGAGCATCCTGCCCACCACG
181
CTCACCACGCTCTGGTCCCTCTCAGTGGCCATCTTTTCTGTTGGGGGCATGATTGGCTCC
241
TTCTCTGTGGGCCTTTTCGTTAACCGCTTTGGCCGGCGGAATTCAATGCTGATGATGAAC
301
CTGCTGGCCTTCGTGTCCGCCGTGCTCATGGGCTTCTCGAAACTGGGCAAGTCCTTTGAG
361
ATGCTGATCCTGGGCCGCTTCATCATCGGTGTGTACTGCGGCCTGACCACAGGCTTCGTG
421
CCCATGTATGTGGGTGAAGTGTCACCCACAGCCTTTCGTGGGGCCCTGGGCACCCTGCAC
481
CAGCTGGGCATCGTCGTCGGCATCCTCATCGCCCAGGTGTTCGGCCTGGACTCCATCATG
541
GGCAACAAGGACCTGTGGCCCCTGCTGCTGAGCATCATCTTCATCCCGGCCCTGCTGCAG
601
TGCATCGTGCTGCCCTTCTGCCCCGAGAGTCCCCGCTTCCTGCTCATCAACCGCAACGAG
661
GAGAACCGGGCCAAGAGTGTGCTAAAGAAGCTGCGCGGGACAGCTGACGTGACCCATGAC
721
CTGCAGGAGATGAAGGAAGAGAGTCGGCAGATGATGCGGGAGAAGAAGGTCACCATCCTG
781
GAGCTGTTCCGCTCCCCCGCCTACCGCCAGCCCATCCTCATCGCTGTGGTGCTGCAGCTG
841
TCCCAGCAGCTGTCTGGCATCAACGCTGTCTTCTATTACTCCACGAGCATCTTCGAGAAG
901
GCGGGGGTGCAGCAGCCTGTGTATGCCACCATTGGCTCCGGTATCGTCAACACGGCCTTC
961
ACTGTCGTGTCGCTGTTTGTGGTGGAGCGAGCAGGCCGGCGGACCCTGCACCTCATAGGC
1021
CTCGCTGGCATGGCGGGTTGTGCCATACTCATGACCATCGCGCTAGCACTGCTGGAGCAG
1081
CTACCCTGGATGTCCTATCTGAGCATCGTGGCCATCTTTGGCTTTGTGGCCTTCTTTGAA
1141
GTGGGTCCTGGCCCCATCCCATGGTTCATCGTGGCTGAACTCTTCAGCCAGGGTCCACGT
1201
CCAGCTGCCATTGCCGTTGCAGGCTTCTCCAACTGGACCTCAAATTTCATTGTGGGCATG
1261
TGCTTCCAGTATGTGGAGCAACTGTGTGGTCCCTACGTCTTCATCATCTTCACTGTGCTC
1321
CTGGTTCTGTTCTTCATCTTCACCTACTTCAAAGTTCCTGAGACTAAAGGCCGGACCTTC
1381
GATGAGATCGCTTCCGGCTTCCGGCAGGGGGGAGCCAGCCAAAGTGATAAGACACCCGAG
1441 GAGCTGTTCCATCCCCTGGGGGCTGATTCCCAAGTGTGA
SEQ ID No. 26 Deduced polypeptide sequence of HsGLUTl
1
MEPSSKKLTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQTWVHRYGESILPTT
61
LTTLWSLSVAI FSVGGMIGSFSVGLFVNRFGRRNSMLMMNLLAFVSAVLMGFSKLGKSFE
121
MLILGRFIIGVYCGLTTGFVPMYVGEVSPTAFRGALGTLHQLGIVVGILIAQVFGLDSIM
181
GNKDLWPLLLSII FIPALLQCIVLPFCPESPRFLLINRNEENRAKSVLKKLRGTADVTHD
241
LQEMKEESRQMMREKKVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSI FEK
301
AGVQQPVYATIGSGIVNTAFTVVSLFVVERAGRRTLHLIGLAGMAGCAILMTIALALLEQ
361
LPWMSYLSIVAIFGFVAFFEVGPGPIPWFIVAELFSQGPRPAAIAVAGFSNWTSNFIVGM
421
CFQYVEQLCGPYVFI IFTVLLVLFFI FTYFKVPETKGRTFDEIASGFRQGGASQSDKTPE
481 ELFHPLGADSQV-
CLAIMS:
1. A transgenic microalgae with increased production of omega-3 LC-PUFAs.
2 . A transgenic microalgae according to claim 1 wherein the microalgae is a
diatom.
3 . A transgenic microalgae according to claim 2 wherein the diatom is P.
tricornutum.
4 . A transgenic microalgae according to a preceding claim wherein the omega-3
LC-PUFA is selected from EPA or DHA.
5 . A transgenic microalgae according to claim 4 wherein the omega-3 LC-PUFA is
DHA.
6 . A transgenic microalgae according to claim 5 wherein the increased DHA
content as a percentage of total fatty acids is increased by at least 1%, 3%, 4%,
5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15% or more compared to a
control microalgae.
7 . A transgenic microalgae according to a preceding claim expressing a nucleic
acid encoding a ∆ δ-elongase.
8 . A transgenic microalgae according to claim 7 wherein said nucleic acid
comprises SEQ ID No. 1 or a sequence that encodes for a ∆ δ-elongase that
has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least
96%, at least 97%, at least 98%, at least 99% homology to SEQ ID No. 2 .
9 . A transgenic microalgae according to any of claims 7 to 9 wherein the
transgenic microalgae further comprises one or more nucleic acids encoding for
a polypeptide involved in regulation of the LC-PUFA pathway.
10. A transgenic microalgae according to claim 9 wherein said nucleic acid encodes
a ∆ -desaturase comprising SEQ ID No. 4 or 6 or a sequence that encodes for
a ∆ δ -desaturase that has at least 75%, at least 80%, at least 85%, at least 90%,
at least 95%, at least 96%, at least 97%, at least 98%, at least 99% homology to
SEQ ID No. 4 or 6 .
11. A transgenic microalgae according to claim 9 wherein said nucleic acid encodes
a ∆ -desaturase comprising SEQ ID No. 8 or 10 or a sequence that encodes for
a 6A-desaturase that has at least 75%, at least 80%, at least 85%, at least 90%,
at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology
to SEQ ID No. 8 or 10.
12. A transgenic microalgae according to any of claims 1 to 4 wherein the omega 3-
fatty acid is EPA.
13. A transgenic microalgae according to claim 12 wherein said microalgae
expresses a nucleic acid that encodes a ∆ -desaturase.
14. A transgenic microalgae according to claim 12 wherein said nucleic acid
encodes a A-6desaturase comprising SEQ ID No. 4 or 6 or a sequence that
encodes for a ∆ -desaturase that has at least 75%, at least 80%, at least 85%,
at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least
99% homology to SEQ ID No. 4 or 6 .
15. A transgenic microalgae according to claim 12 wherein said nucleic acid
encodes a ∆ -desaturase comprising SEQ ID No. 8 or 10 or a sequence that
encodes for a ∆ -desaturase that has at least 75%, at least 80%, at least 85%,
at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least
99% homology to SEQ ID No. 8 or 10.
16. A transgenic microalgae according to any of claims 7 to 15 wherein said nucleic
acid further comprises a regulatory sequence.
17. The use of a transgenic microalgae according to a preceding claim in producing
omega-3 LC-PUFAs or increasing one or more omega-3 LC-PUFAs.
18. The use according to claim 17 wherein the omega-3 LC-PUFA is EPA or DHA.
19. The use according to claim 17 wherein the omega-3 LC-PUFAs is DHA.
20. A method for producing transgenic microalgae with increased omega-3 LC-
PUFAs content.
2 1. A method according to claim 20 wherein the omega-3 LC-PUFA is DHA and the
method comprises transforming a microalgae with a nucleic acid encoding a ∆ 5-
elongase.
22. A method according to claim 20 wherein the omega-3 LC-PUFA is EPA and the
method comprises transforming a microalgae with a nucleic acid encoding a ∆ 6-
desaturase.
23. A method for increasing production of one of more omega-3 LC-PUFA in
microalgae comprising
a) cultivating a transgenic microalgae according to any of claims 1 to 16 under
conditions which allow for the production of one of more omega-3 LC-PUFAs
and
b) obtaining said one of more omega-3 LC-PUFA from the transgenic
microalgae.
24. A method according to claim 23 wherein said omega-3 LC-PUFA is DHA and
the method comprises
a) cultivating a transgenic microalgae according to any of claims 5 to 11 or 16
under conditions which allow for the production of DHA and
b) obtaining said DHA from the transgenic microalgae.
25. A method according to claim 20 wherein said omega- 3 LC-PUFA is EPA and
the method comprises
a) cultivating a transgenic microalgae according to any of claims 12 to 16 under
conditions which allow for the production of EPA and
b) obtaining said EPA from the transgenic microalgae.
26. An oil isolated from a microalgae according to any of claims 1 to 16 or a
foodstuff, feedstuff, nutriceutical or cosmetic obtained from a microalgae
according to any of claims 1 to 16.
27. A composition comprising a transgenic microalgae according to any of claims 1
to 16 or an oil according to claim 26.
28. A composition comprising a transgenic microalgae according to any of claims 1
to 16 for use as a medicament.
29. A composition comprising a transgenic microalgae according to any of claims 1
to 16 for use in the treatment or prevention of cardiovascular conditions,
including atherosclerosis, thrombosis, high blood pressure, myocardial infarction
and atherosclerosis, inflammatory conditions, depression, cognitive decline,
arthritis, eczema, metabolic syndrome and type I I diabetes.
30. A transgenic microalgae according to any of claims 1 to 16 or a composition
comprising a transgenic microalgae according to any of claims 1 to 16 for use
as a foodstuff, feedstuff, nutriceutical or cosmetic.
3 1. A method for making a feedstuff comprising a) cultivating a transgenic
microalgae comprising a heterologous transgene as defined in any of claims 1-
16 under conditions which allow for the production of one of more omega-3 LC-
PUFAs and
b) obtaining said one of more omega-3 LC-PUFA from the transgenic
microalgae.
32. An isolated nucleic acid comprising SEQ ID No. 7 or 9 encoding A6-desaturase
(Ost809A6) comprising SEQ ID No. 8 or 10, a functional variant thereof or a ∆ 6-
desaturase that has at least 75%, at least 80%, at least 85%, at least 90%, at
least 95%, at least 96%, at least 97%, at least 98%, at least 99% homology to
SEQ ID No. 8 or 11.
33. An isolated nucleic acid comprising SEQ ID No. 15 or 17 encoding a ∆ 4-
desaturase (Ost809A4) comprising SEQ ID No. 16 or 18, a functional variant
thereof or a A4-desaturase that has at least 75%, at least 80%, at least 85%, at
least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%
homology to SEQ ID No. 16 or 18.
34. An isolated nucleic acid comprising SEQ ID No. 19 encoding A6-elongase
(FcEL06) comprising ID No. 20 a functional variant thereof or a A6-elongase
that has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at
least 96%, at least 97%, at least 98%, at least 99% homology to SEQ ID No. 20.
35. An isolated nucleic acid comprising SEQ ID No. 2 1 encoding ∆ δ-desaturase
comprising ID No. 22 a functional variant thereof or a A6-elongase that has at
least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%,
at least 97%, at least 98%, at least 99% homology to SEQ ID No. 22.
36. A vector comprising an isolated nucleic according to claim 32, 33, 34 and/or 35.
37. A host cell comprising a vector according to claim 36.
38. A host cell according to claim 37 wherein the host cell is an algae or higher
plant cell.
39. The use of an isolated nucleic according to claim 32, 33, 34 and/or 34 in
increasing the production of omega-3 LC-PUFAs in microalgae, the preparation
of a foodstuff, feedstuff, nutriceutical, cosmetic or medicament.
40. The use according to claim 39 wherein the omega-3 LC-PUFAs is EPA or DHA.
4 1. A method for increasing production of one of more omega-3 LC-PUFA in
microalgae comprising
a) cultivating a transgenic microalgae comprising a heterologous transgene
comprising one or more of the nucleic acids defined in claims 30, 3 1 or 32
under conditions which allow for the production of one of more omega-3 LC-
PUFAs and
b) obtaining said one of more omega-3 LC-PUFA from the transgenic
microalgae.
42. A transgenic organism with increased DHA levels expressing a heterologous
∆ δ-elongase.
43. A transgenic organism according to claim 42 wherein the ∆ δ-elongase is a ∆ 5-
elongase from Ostreococcus tauri.
44. A transgenic organism according to claim 42 and 43 wherein no other
heterologous transgenes involved in the regulation of the LC-PUFAs biosynthetic
pathway are expressed in said organism.
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